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Abstract
Prior work in causal modeling has focused primarily on learning graph structures
and parameters to model data generating processes from observational or experimental
data, while the focus of the literature-based discovery paradigm was to identify novel
therapeutic hypotheses in publicly available knowledge. The critical contribution of this
dissertation is to refashion the literature-based discovery paradigm as a means to populate
causal models with relevant covariates to abet causal inference. In particular, this
dissertation describes a generalizable framework for mapping from causal propositions in
the literature to subgraphs populated by instantiated variables that reflect observational
data. The observational data are those derived from electronic health records. The
purpose of causal inference is to detect adverse drug event signals. The Principle of the
Common Cause is exploited as a heuristic for a defeasible practical logic. The
fundamental intuition is that improbable co-occurrences can be “explained away” with
reference to a common cause, or confounder. Semantic constraints in literature-based
discovery can be leveraged to identify such covariates. Further, the asymmetric semantic
constraints of causal propositions map directly to the topology of causal graphs as
directed edges. The hypothesis is that causal models conditioned on sets of such
covariates will improve upon the performance of purely statistical techniques for
detecting adverse drug event signals. By improving upon previous work in purely EHRbased pharmacovigilance, these results establish the utility of this scalable approach to
automated causal inference.
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Chapter 1: Introduction
Long after the solstice, near the equinox, wintry weather returned, and at the
actual equinoctial period there were southerly winds with snow, but not for long.
The spring southerly again, with no winds; many rains throughout until the Dog
Star. The summer was clear and warm, with waves of stifling heat. The Etesian
winds were faint and intermittent. But, on the other hand, near the rising of
Arcturus there were heavy rains with northerly winds.
The year having proved southerly, wet and mild, in the winter the general health
was good except for the consumptives, who will be described in due course.
Hippocrates, Epidemics III, pg. 241
Scientific understanding progresses when evidence is marshaled to explain some hitherto
misunderstood aspect of our world. As findings are shared, a debate within the scientific
community ensues over their meaning and validity. The validity of any study hinges in
part upon the integrity of the data and the suitability of the methods used to analyze them.
Techniques that are well-suited for analyzing experimental data may not be applied
without modification to assay observational data. In other words, novel approaches must
be developed that account for the unique characteristics of any new stream of empirical
evidence.

1

This dissertation explores the accommodations necessary for using observational
clinical data derived from electronic health records2 (EHRs) to detect putative
drug/adverse event relationships. An adverse event is defined as:
“An appreciably harmful or unpleasant reaction, resulting from an intervention
related to the use of a medicinal product, which predicts hazard from future
administration and warrants prevention or specific treatment, or alteration of the
dosage regimen, or withdrawal of the product” (Edwards & Aronson, 2000).
Randomized controlled trials (RCTs) were developed to determine the efficacy and safety
of novel treatments for disease and are considered a gold standard in this regard.
However, the capacity of RCTs is limited concerning what they can tell about either
effectiveness or safety under conditions of everyday use (Cartwright, 2007). Spontaneous
Reporting Systems such as the Federal Adverse Event Reporting System (FAERS) in the
United States have been developed to gather data for pharmacovigilance, or the postmarketing surveillance of drugs and other treatments (Federal Drug Administration
Adverse Event Reporting System, 2017). However, researchers have established that
adverse events are underreported (Alvarez-Requejo et al., 1998; Gahr, Eller, Connemann,
& Schonfeldt-Lecuona, 2016; Hasford, Goettler, Munter, & Muller-Oerlinghausen, 2002;
Perez Garcia & Figueras, 2011).
Electronic Health Records have been proposed as a source of data to complement
spontaneous reporting systems. Indeed, EHR represents a rich but imperfect record of

2

According to International Standards Organization, an electronic health record is defined as “repository
of information regarding the health status of a subject of care, in computer processable form”
(“ISO/TR 20514:2005(en), Health informatics — Electronic health record — Definition, scope and
context,” n.d.).
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routine clinical practice and can be used to complement other sources of data (Hersh et
al., 2013). The HITECH Act of 2009 mandates the “meaningful use” or secondary reuse
of electronic health records (EHR) in research to improve public health outcomes
(Henricks, 2011). As the bulk of data of interest are embedded in the unstructured text, it
is necessary that these data undergo extensive text processing to make them amenable to
computation and downstream analysis (Haerian et al., 2012; X. Wang, Hripcsak,
Markatou, & Friedman, 2009). Another issue, one that is the focus of this dissertation, is
that of confounding, or the presence of variables that may introduce bias if left
uncontrolled (Brookhart, Stürmer, Glynn, Rassen, & Schneeweiss, 2010; S. Greenland &
Morgenstern, 2001).
Unrecognized confounding factors are a significant analytic concern that can lead
to erroneous conclusions (S. Greenland & Morgenstern, 2001). However, if these
covariates are identified, they may help to “explain away” spurious associations and
facilitate detection of significant relationships. For example, a strong initial correlation
between the medication rosiglitazone may be observed with the adverse event acute
myocardial infarction (Dore, Trivedi, Mor, & Lapane, 2009; Florez et al., 2015).
However, if diabetes mellitus is included as a variable, the strength of this association
diminishes. The inclusion of the comorbidity of diabetes makes sense since rosiglitazone
is used to treat diabetes mellitus and diabetes mellitus is a known to cause heart attacks
(Hanssen et al., 2018). Moreover, diabetes mellitus is a mutual cause of both the

3

treatment3 (rosiglitazone exposure) and the adverse event (acute myocardial infarction).
Note, however, that the “causal” interpretation of confounding outlined above has only
slowly gained traction only in the last thirty-five or so years4 (J. Pearl & Mackenzie,
2018). This interpretation, referred to as “the principle of the common cause,” was first
noted in 1956 in the philosophy of science literature (Reichenbach, 2012). The common
cause principle is illustrated in Figure 1.

Figure 1. Illustration of a “true confounder” (S. Greenland, Pearl, & Robins, 1999). This
illustration demonstrates the “forking pattern” exhibited by a confounder5 on a putative
predictor/explanatory/exposure variable (drug) and an outcome variable by an extraneous
variable (a variable besides the exposure).

3

Were it not for diabetes, the patient would not likely have been exposed to rosiglitazone. “To treat” is
usually thought of as having the subject (the treatment, e.g., medication or device) exert its action (as a
force dynamic predicate (Levin & Hovav, 2005)) upon an object (some pathological phenotype), but here it
may be thought of in terms causation with the object exerting its influence, i.e., causing the exposure.
4
More technically exacting definitions exist, but this explanation conveys the core of what is meant by
“confounder” (T. J. VanderWeele & Shpitser, 2013).
5
Greenland et al. offer this definition of confounder: “the variable is an ancestor (cause) of the outcome,
and (2), the variable is associated with the exposure, but (3) the variable is not a descendant (effect) of the
exposure or outcome” (S. Greenland, Pearl, & Robins, 1999; Weinberg, 1992).

4

The exploitation of observational EHR data for research purposes necessitates a
means to identify such confounding variables, variables that are known to affect both the
predictor (e.g., drug or pathogen exposures, genetic variants) and the health outcome of
interest. Such exogenous factors are unavoidable in EHR data as clinical data are not
collected under controlled experimental conditions (Brookhart, Stürmer, et al., 2010; S.
Greenland & Morgenstern, 2001). Unless confounding bias is mitigated, the quality of
analysis will be suboptimal (S. Greenland & Morgenstern, 2001). One approach to
confounding control is by identifying confounders and including them into one’s
statistical or causal model through experience or domain knowledge. The problem of
specifying a causal model consistent with background knowledge is referred to as the
“identification problem” (Freedman, 2004; Han, Xie, Wu, Li, & Zhu, 2015; W. Li, Jiang,
Geng, & Zhou, 2018; J. Pearl & Mackenzie, 2018). If more powerful methods are not
developed to address confounding, the EHR is likely to remain an underutilized resource
(Brookhart, Stürmer, et al., 2010; Hersh et al., 2013; Samuels, McGrath, Fetzer, Mittal, &
Bourgoine, 2015).
This dissertation directly addresses the identification problem of causal modeling
within a meta-statistical causal modeling framework. Here, I emphasize “meta-statistical”
because descriptive statistics derived from data alone are insufficient to identify
confounders or other types of causal relationships (Amirkhani, Rahmati, Lucas, &
Hommersom, 2016; Cooper, Gregory F., 1984; Heckerman, Geiger, & Chickering, 1995;
Meek, 2013; J. Pearl & Mackenzie, 2018; Judea Pearl, 2009, 2010).
5

Causal modeling may be thought of as a fusion method wherein assumptions from
background knowledge are combined with empirical data (experimental, observational,
or both) (Cooper & Yoo, 2013) to provide insight into the mechanisms responsible for
generating inter-variable covariance patterns (Heckerman et al., 1995; Meek, 2013, 2013;
Judea Pearl, 2009; P. Spirtes, Glymour, & Scheines, 2012).
A universally satisfactory definition of causality eludes scholars and remains a
topic of active research. This dissertation assumes a classic counterfactual definition of
causality6: “were it not for X, Y would not have happened” (Beebee, Hitchcock, &
Menzies, 2009; Hume, 1748; Lewis, 1979; Mackie & Press, 1980; Judea Pearl, 2009;
Salmon, 1984). Relationships due to causation and probabilistic association often share
common attributes: temporal precedence and spatial contiguity. To use an example from
Cheng et al., a rooster may crow before dawn, but sound does not and cannot levitate
objects7 (Holyoak & Cheng, 2011). A key distinction is that a causal relationship is by
definition not merely necessary8, but stable under varying conditions and sufficient to
produce an effect (Mackie & Press, 1980; Judea Pearl, 2009; Woodward, 2016).
Given background knowledge of confounders identified in the literature9, the
present work describes a causal modeling framework to use observational clinical data
6

Is causality a stochastic process with deterministic surface manifestations or deterministic process with
stochastic surface manifestations? David Hume offered not one but at least three distinct definitions of
causality in his works (Beebee, Hitchcock, & Menzies, 2009).
7
Per Glymour in personal note: “the rooster’s crow does levitate some objects, e.g., sleepers who hear it,
just like a trumpet at dawn causes soldiers to rise.”
8
Oxygen is necessary for arson to occur, but it is not sufficient. Oxygen is, however, an “enabling
condition.”
9
By contrast, in “causal discovery,” a closely related area of research, one may not necessarily entertain
strong assumptions about the causal relationships, if there are any, between the entities under study.
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derived from EHR to determine the likelihood that a particular medication might cause an
adverse event. This domain knowledge provides a “causal story” to help filter out more
likely cause-and-effect drug/adverse event relationships from less likely drug/adverse
event pairs that tend to frequently co-occur due to their having a common cause (J. Pearl,
Glymour, & Jewell, 2016). The associational methods of traditional statistics can only
indicate statistical correlation, and not determine causal relationships, yet such
relationships are what is desired in the sciences (C. Glymour, Scheines, & Spirtes, 2014;
Mackie & Press, 1980; Salmon, 1984).
Before proceeding further, a necessary clarification should be made to emphasize
the distinction between the ends of causal modeling and the evidentiary establishment of
causal claims. Confusion remains as the selfsame word is used for both (both hypothesis
and its establishment) and that both rest on “external validation” (Reeves et al., 2014).
Sir Bradford Hill defined a set of criteria for establishing causal relationships in
medicine: these criteria include prevalence, exposure, incidence, consistency,
temporality, biological gradient, and so forth10 (Hill, 1965). The establishment of a
causal claim is a product of consensus mediated by the scientific community and a body
of evidence11 (Thagard, 2018). A causal claim requires explanatory coherence between
the hypothesis and the evidence to be accepted. The elements of explanatory coherence

10

Robert Koch in 1882 described another related set of criteria required to demonstrate causal
relationships between microorganisms and disease, called the “Koch postulates” (Brock, 1961; Thagard,
2018).
11
Thagard assumes that the discussion is about social establishment rather than the rational justification of
causal claims.
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include voluminous evidence of consistent biological plausible empirical data and if
possible randomized experimentation to rule out confounding factors. By contrast, causal
modeling cannot by itself establish a causal relationship, as this is a social process
mitigated over time within the scientific community, and as such beyond the purview of
the present discussion (Thagard, 2018).
Rather, causal modeling is a tool for data-driven exploration of causal
hypotheses. Its inputs are data and causal assumptions (including domain knowledge),
and the output of these artifacts is a causal model, i.e., a configurable blueprint of the
mechanisms that underlie the variables so subsumed12 (Cartwright, 2004; J. Pearl et al.,
2016; J. Pearl & Mackenzie, 2018).
Causal modeling incurs an extra cost beyond raw data, as domain knowledge of
confounders (or “a causal story”) facilitates its practical application and hence, the
discernment of causal relationships (J. Pearl et al., 2016). Since it is not feasible to
perform causal analysis without such knowledge (although the data can in fact indicate
confounders or their absence), causal modeling at scale is not tractable without some
means to automate the identification of contextually relevant covariates.
One promising source of domain knowledge to populate causal models is the
biomedical literature. If it were possible to identify confounding variables13 in the

12

Cartwright writes: “Old causal knowledge must be supplied for new causal knowledge to be had”
(Cartwright, 1994)
13
Other types or “roles” of causal variables exist: mediators which lie along the causal path from an
explanatory variable to the outcome (Richiardi, Bellocco, & Zugna, 2013; T. J. VanderWeele, 2012, 2012),
instrumental variables which are correlated with the explanatory variable but not the outcome, to name a
few (Bowden & Turkington, 1985).
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literature, this would obviate the need for manual construction of causal models by
domain experts and hence permit the application of causal modeling and the evaluation of
causal hypotheses at scale.
The primary hypothesis of this dissertation is that causal models informed
by domain knowledge will outperform purely statistical methods for detecting
drug/adverse event relationships in clinical data derived from EHR. To this end, this
dissertation develops and describes a concrete application of this approach within the
problem domain clinical research informatics (as it pertains to the secondary re-use of
electronic health records), and more specifically to the field of pharmacovigilance. This
approach leverages the literature to predict and identify confounders in EHR-derived data
and uses these covariates within a probabilistic generative causal modeling framework to
estimate the magnitude of drug/adverse event relationships. To access domain knowledge
in the literature, this work describes techniques derived from Literature-Based Discovery
(LBD) methods. LBD is a program of research pioneered by librarian-turned-researcher
Don Swanson in the 1980s that focuses on identifying implicit relationships embedded in
publicly available knowledge as a means to generate novel hypotheses14 (Bruza &
Weeber, 2008). The intuition behind LBD, which Swanson referred to as the “A-B-C”
model is as follows: A is associated with B and B is associated with C in the literature
(Smalheiser, 2012, 2017). The task of LBD is to identify what “B” is, referred to as a
“bridging term” (Hristovski, Friedman, Rindflesch, & Peterlin, 2006). In the case of

14

More recently, LBD work has expanded into detecting of pharmacovigilance signals in the biomedical
literature (Shang, Xu, Rindflesch, & Cohen, 2014).
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causal modeling for pharmacovigilance, the confounders identified in the literature derive
from these bridging terms.
This dissertation tests the hypothesis above with three specific aims: Aim 1
describes the task of creating a database of clinical data derived from EHR and
establishing a baseline using unadjusted traditional statistical methods (logistic
regression) using a curated publicly available reference data set. Aim 2 defines a method
to integrate the literature-identified variables into the causal graphs with a focus on the
graph structure. Aim 3 presents a strategy to estimate average treatment effects using
conditional probability queries on data simulated from “modified” or “mutilated” causal
graphs.
These aims are described in detail as follows:
1.1 SPECIFIC AIM I: Extract clinical data from EHR and evaluate baselines scores
using traditional statistical methods with and without confounding adjustment
(from incorporating literature derived covariates).
Objective: Extract clinical data from a clinical data repository after having
attained approval from the [UTHealth] IRB, and construct a statistical baseline
using logistic regression for comparison with causal models.
Rationale: Create clinical data database and obtain a performance baseline for
EHR-based pharmacovigilance for comparison with more sophisticated models
that will incorporate literature-derived confounders. Demonstrate the feasibility
of using LBD to identify contextually relevant confounders given a drug and an
adverse event as “cue terms.”
10

Research Question(s): How difficult is it to detect pharmacovigilance signals in
EHR with traditional statistical methods (logistic regression)? Do literaturederived confounders help to reduce confounding bias in statistical models of
EHR data? Which discovery patterns are most effective at reducing
confounding? Can the literature be used to identify confounders? Can the
identified confounders be used to “explain away” spurious correlations in
observational clinical data, thereby improving the accuracy of predictions based
on statistical associations?
1.1.1

Extract clinical data from EHR that will be utilized in evaluating the literatureidentified covariates.

1.1.2

Evaluate baseline performance both with and without confounding adjustments.
Use a publicly available reference dataset15 with EHR data by calculating the
Area Under the Curve of a Receiver Operator Characteristic (AUROC) from the
aggregated ranked-order logistic regression coefficients for each drug/adverse
event pair in the reference dataset (Ryan, Schuemie, et al., 2013; UTHealth BIG.,
2017).

1.2 SPECIFIC AIM II: Develop and test the utility of the literature-identified
confounders in causal models and compare the results with those from statistical
models.
Objective: Incorporate literature-identified confounders into causal models.

15

Reference datasets in pharmacovigilance are used for methodological evaluation of novel methods for
detecting drug/adverse event signals that may be worthy of further investigation.
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Rationale: Demonstrate the utility of graph topology learned from EHR data
within a pharmacovigilance use case, a core subfield of biomedicine.
Research Question(s): How useful is the structure of causal graphs for
disentangling pharmacovigilance signal from noise? What is the optimal number
of confounding variable candidates to incorporate into a model? Is automated
causal inference feasible using literature-based discovery as a feature selection
technique for potential confounders?
1.2.1

Define a method to integrate not only the literature-identified variables, but a
causal subgraph16 of these covariates into causal models. Evaluate the utility of
the literature-derived confounders on the task of disentangling adverse event
signals from noise in logistic regression models of EHR data using a publicly
available reference dataset (Ryan, Schuemie, et al., 2013; UTHealth BIG., 2017).

1.2.2

Evaluate the utility of causal models with literature-identified confounders and
graph structure for improving signals of causal drug/adverse drug event
relationships.

1.2.3

Evaluate the utility of causal models with literature-identified confounders and
graph structure for improving signals of causal drug/adverse event relationships.
Use a publicly available reference set with EHR data by calculating the AUROC
from the aggregated ranked-order logistic regression coefficients for each

16

“Causal subgraph” refers to the directed acyclic graph (which consists of nodes and directed edges, or
arrows) wherein domain knowledge facilitates the orientation of the edges of the literature-derived
confounders, i.e., the edges point fork-like from the confounder to the medication and putative adverse
event.

12

drug/adverse event pair in the reference dataset (Ryan, Schuemie, et al., 2013;
UTHealth BIG., 2017).

1.3 SPECIFIC AIM III: Develop and test methods to estimate Average Treatment
Effect (ATE) from simulations using causal models informed by literature-derived
confounders.
Objective: Incorporate literature-identified confounders into causal models and
estimate treatment effects using simulated data from the topology and structures
learned from the EHR data.
Rationale: Demonstrate the generalizability of causal models with the automatic
selection of literature-derived confounders using another set of clinical data derived
from EHR and another reference dataset (Rave Harpaz, 2014).
Research Question(s): How useful is parameter estimation17 for reducing error? Is it
possible to calculate average treatment effect?
1.3.1

Develop the data generating process capabilities of causal models and exploit
these simulations to estimate Average Treatment Effect (ATE). Evaluate methods
using a publicly available reference set with EHR data by calculating the AUROC
from the aggregated ranked-order logistic regression coefficients for each
drug/adverse event pair in the reference dataset (Ryan, Schuemie, et al., 2013;
UTHealth BIG., 2017).

17

“Parameter estimation” refers to estimating the strength of the causal relationship that is inferred
between, for example, a particular medication and an alleged adverse event.

13

The research domains addressed by this thesis include literature-based discovery,
causal modeling and discovery, and pharmacovigilance methodology. Natural language
processing (NLP) facilitates this work but is not the theoretical focus. The literaturebased discovery research paradigm is used as a means of accessing salient domain
knowledge given a problem space defined by cue terms (a drug and an adverse event).
The use of LBD methods to identify confounding variables is a novel application of these
methods. Literature-based discovery in our configuration harnesses semantic constraints
in the form of predicates to identify salient covariates for our models. In the approach,
literature-based discovery is used to automate feature selection combined with constraints
on the directed acyclic graphs in our causal models.
The contributions of this thesis to the discourse of biomedical informatics are as
follows:
1. Demonstration of a novel domain of application for LBD methods.
2. Demonstration of LBD methods to automatically identify confounding
variables and improve the accuracy of predictive models (both classical
statistical and contemporary causal modeling methods).
3. Demonstration of how domain knowledge may be used as a means to
constrain hypothesis space and automatically devise hypothetical
explanations of empirical observational data. The automated generation of
hypotheses to explain observations using domain knowledge is tantamount
to implementing what is referred to as a “defeasible practical logic” in

14

silico (Dziurosz-Serafinowicz, 2012; Gabbay & Woods, 2005;
Reichenbach, 2012).
4. The methods proposed may be generalized to other areas of biomedicine.
For example, these methods may be adapted to identify control groups for
RCTs (Fokkema, Smits, Zeileis, Hothorn, & Kelderman, 2017).
As a desirable bonus feature, the graphs that result from the approach should be
clinically insightful. Interpretability being a notable feature of our approach, clinicians
may use the graphs to enhance their comprehension of the underlying pathophysiology,
inspire unexpected questions, or discern potential risk factors when considering a course
of treatment, thereby improving health outcomes.
This dissertation is organized as follows. Chapter 2 reviews previous work in
EHR-based pharmacovigilance, identify methodological gaps and provide the
background and motivation for understanding the impetus for refashioning the literaturebased discovery framework to inform causal models using EHR-based observational
clinical data as a primary data source. Chapter 3 presents an overview of literature-based
discovery and causal modeling components and how they complement each other.
Chapter 4 tests Specific Aim 1 by incorporating the confounding variable candidates
identified in the literature into logistic regression models. Chapter 5 and Chapter 6
implement and evaluate variants of the causal modeling, and discuss their implications
for the secondary analysis of observational data (addressing Specific Aim 2 and 3).
Finally, Chapter 7 summarizes the contributions that this work offers to the practice and

15

theory of informatics, discusses the limitations of the present study, and presents
promising future directions for this program of research.

16

Chapter 2: Literature Review
There are also a number of things for which it is not enough to name one cause,
but many, one of which is nevertheless the true cause: just as if you should
yourself see some man’s body lying lifeless at a distance, you may perhaps think
proper to name all the causes of death in order that the one true cause of the
man’s death be named. For you could not prove that steel or cold had been the
death of him, or disease, or it may be poison, but we know that what has
happened to him is something of this sort.
Lucretius, De Rerum Natura, 6.703 – 709

This chapter provides an overview of related work in pharmacovigilance, causal
inference, and literature-based discovery. To circumscribe the scope of the current
review, unresolved challenges of using clinical text derived from electronic health record
(EHR) systems for pharmacovigilance will be presented first. Noting the unresolved
challenges will help to specify the problem, and thereby isolate the gaps in the current
literature, that this dissertation seeks to address.
2.1 Pharmacovigilance
Some 770,000 adverse events occur annually in the United States alone, resulting
in morbidity, mortality, and the increased cost is a considerable onus on healthcare

17

systems worldwide18 (Diaz-Garelli, Bernstam, Mse, Rahbar, & Johnson, 2015; Hersh et
al., 2013). Pharmacovigilance aims to address the set of challenges posed by adverse
events, including those detected after drugs are released to market after regulatory
approval. It seeks to ascertain the risks and benefits of exposure, identify
contraindications, and in extreme cases withdraw products altogether in the event of
severe adverse events19 (J. K. Aronson, 2017). Recognizing the need to monitor adverse
effects of drugs systematically, since surveillance cannot and does not end after approval,
regulatory agencies such as the US Food and Drug Administration (FDA) have
implemented spontaneous reporting systems, through which clinicians and administrators
of clinical trials can report potential adverse events as they are observed. However,
spontaneous reporting systems such as the Federal Adverse Event Report System
(FAERS) have limitations, including incomplete clinical information, under-reporting of
side-effects, and unacknowledged sources of bias (Alvarez-Requejo et al., 1998; Federal
Drug Administration Adverse Event Reporting System, 2017; Hasford et al., 2002).
Researchers in pharmacovigilance have sought to evaluate the utility of other
sources of data as input for pharmacovigilance methods. These have included both
structured and unstructured data and from social media, claims data, and clinical data
derived from electronic health record (EHR) systems (Edlinger et al., 2014; Eshleman &
Singh, 2016; Haerian et al., 2012; Rave Harpaz et al., 2017; Rave Harpaz, DuMouchel, &

18

In one UK study, adverse events resulted in ~ 6.5% of all hospital admissions (Pirmohamed et al.,
2004).
19
For a historical introduction to the history of pharmacovigilance from the case of thalidomide which led
to the passage of the Kefauver-Harris Act of 1962, and the Vioxx case, see (Nesi, 2008; “News & Events >
50 Years,” 2013; Stephens & Brynner, 2009).
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Shah, 2015; Hersh et al., 2013; Y. Li et al., 2014; Lin & Schneeweiss, 2016; Liu, Zhao, &
Zhang, 2016; Pierce et al., 2017; Samuels et al., 2015; X. Wang et al., 2009). The focus
of this dissertation is on the use of unstructured clinical text recorded in EHR systems.
Clinical text (notes) recorded in EHR systems are a potentially useful source of
data for pharmacovigilance, yet drawing reliable conclusions from routinely collected
clinical data is notoriously challenging (Diaz-Garelli et al., 2015; Hersh et al., 2013). In
the pharmacovigilance literature, the term “signal” refers to anything that warrants further
investigation. Signals may be easier to detect in clinical trials where subjects are
deliberately monitored for side-effects, by contrast data embedded clinical narratives
were not collected for pharmacovigilance, and are often beset with redundancy or
missing data, use of non-standard abbreviations, misspellings, and so on. In addition,
clinical data contain confounding variables (Hersh et al., 2013; Y. Li et al., 2014).
2.1.2 Confounding in Electronic Health Records
An association between two variables, let’s denote them X and Y, cannot be
explained with reference only to themselves (Wasserman, 2013). One needs to introduce
at least one other variable, and usually many other such covariates, to rule out non-causal
reasons for an observed statistical correlation. If one were to possess domain knowledge
of X and Y, one might include a third variable Z that experience or domain knowledge
has determined may be responsible for producing them both and increasing the likelihood
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of their co-occurrence (referred to as the principle of the common cause)20 (Reichenbach,
2012). For example, there may be a robust initial correlation between a drug, e.g.,
rosiglitazone, and myocardial infarction. However, upon the introduction of the third
variable of diabetes, which rosiglitazone is used to treat and which also is known to cause
heart attacks, the robust initial correlation is diminished. The identification of such
covariates may be acquired either through analysis of the data itself or by experience or
domain knowledge (Y. Li et al., 2014a). Given such knowledge, the determination of the
existence and/or magnitude of the effect of X on Y may be measured in one of two ways:
1.) By a randomized experiment, with samples chosen for similar risk
characteristics, e.g., those who are carriers of an allele associated with risk of developing
a disease or family history.
2.) From non-experimental observational data that infer the influence of latent
confounding or with the inclusion of such covariates into statistical and/or causal models
as shall subsequently be described.
Experimental conditions are by all means preferred when possible since the
researcher may carefully control the introduction of exogenous or independent variables
to measure the outcome and determine the existence and magnitude of any causal
relationship. However, the opportunity and the advantages of such conditions may not
always be feasible: randomized control trials may be unethical to obtain or intractably
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The Principle of the Common Cause does not always hold: correlation may be present in the
absence of a common cause, e.g., the number of pirates and atmospheric carbon.
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expensive, e.g., studying the relationship between tobacco use and lung cancer (Kovesdy
& Kalantar-Zadeh, 2012). This brings us to the focus of this dissertation: the
determination and estimation of the risk of adverse events arising from the exposure to
medications using non-experimental data, specifically observational clinical data derived
from unstructured clinical text (notes) in electronic health records 21.
The following section will discuss study designs of related work in
pharmacovigilance using clinical data derived from electronic health records within the
context of confounding.
2.1.2.1 Confounding control
If individual variables exogenous to but influencing an X and a Y of interest may
be identified and have been measured, it may be possible to determine the existence of a
relationship and/or estimated measure of the risk of an adverse event given exposure
from observational data under certain conditions (C. Wang, Dominici, Parmigiani, &
Zigler, 2015; G. Wang, Jung, Winnenburg, & Shah, 2015; X. Wang et al., 2009).
Researchers have developed a convenient taxonomy for the various types of confounder
that may be present in electronic health records for pharmacovigilance. These include
confounding by co-morbidity, confounding by co-medication (where exposure to another
drug is responsible for producing the adverse event), and confounding by indication
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As noted in Chapter 1, other forms of non-experimental observational data, e.g., claims and social media
data, exist and are available for research; however, these lie beyond the scope of the present dissertation.
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(wherein complications from the disease being treated may be culpable for producing the
adverse event) (Y. Li et al., 2014a).

2.1.2.2 Confounding and Confounders
Confounding is present when the influence of common causes, alternate
etiologies, or uncontrolled latent variables introduce bias in one’s model (Judea Pearl,
2009; T. J. VanderWeele & Shpitser, 2011, 2013). The term “confounding” is the more
generally accepted word for the overarching phenomenon that denotes bias endemic to
observational data, while the term “confounder,” which refers to an individual variable
that introduces confounding, has only recently gained acceptance and traction among
researchers (T. J. VanderWeele & Shpitser, 2013). Etymologically, confounding refers to
a state of being mixed up or confused (“confound | Definition of confound in English by
Oxford Dictionaries,” n.d.).
If a confounder can be identified, then it may be incorporated into one’s model to
de-confound that model and reduce confounding and hence potentially improve the
quality of one’s analysis. Insofar as it reduces bias due to confounding, it is a proper
confounder (S. Greenland et al., 1999; Judea Pearl, 2009; T. J. VanderWeele & Shpitser,
2013). However, if such a covariate does not serve to improve the model, then it should
be ignored, a condition that is referred to as “ignorability” (S. Greenland & Morgenstern,
2001; S. Greenland & Robins, 1986; Sander Greenland & Robins, 2009).
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2.1.2.3 Selection Bias, Measurement Error, and Confounding22
Since observational clinical data were not produced under experimental
conditions, other types of bias may be present. These may include selection bias and
measurement error (Haneuse, 2016; Talbot & Aronson, 2012). Selection bias occurs
when a sample of individuals for a study is not properly randomized23 and is therefore not
representative (Haneuse, 2016; Miguel A. Hernan, Hernandez-Diaz, & Robins, 2004).
For example, particular practices may have self-selected for patients that could be
particularly vulnerable to an adverse event. Additionally, errors may be introduced in
measurement in data collection as a result of typographical errors or other factors, such as
clinician fatigue or burnout (Collier, 2017; EHRIntelligence, 2018; Wachter &
Goldsmith, 2018). However, however methods to control these other sources of bias are
beyond the scope of this dissertation and have been addressed elsewhere (Cartwright,
2004; Elwert & Winship, 2014; Haneuse, 2016; Miguel A. Hernan et al., 2004; P. H. Lee
& Burstyn, 2016; Suzuki, Tsuda, Mitsuhashi, Mansournia, & Yamamoto, 2016). Instead,
this dissertation focuses on the prospect of controlling exogenous variables that may be
identified in the clinical text. The next section describes methods to control for
confounding either through analysis of the data or by other means, such as the application
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I acknowledge that I am excluding missing data bias, reporting bias, design bias, protophatic bias,
clinician facility bias, clinical NLP bias, and so on.
23
Glymour in personal note: “randomization does not guarantee representativeness, nor does absence of
randomization entail that a sample is not representative.”
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of background knowledge extraneous to the raw data inputs to inform structural causal
models (the focus of this dissertation).

2.2 Related Work: confounding control in EHR-based pharmacovigilance
Confounding control in observational data study designs may be categorized by
two general classes: control by design (e.g., cohort studies, case-control) and control by
analysis (Talbot & Aronson, 2012).
2.2.1 Control by Design
Cohort and case-control models are two methods that have been proposed to
address confounding in EHR data that can be characterized by “control by design”
(Talbot & Aronson, 2012). Similar to RCTs, subgroups are identified and included in
these studies for their respective populations having similar risk factors and other
characteristics “with the purpose of mitigating the effects of confounders” (Lewallen &
Courtright, 1998). A primary difference between case-control and cohort studies is that
case-control studies are retrospective and cohort studies are prospective (Lanza, Ravaud,
Riveros, & Dechartres, 2016; Pugh, Bronsvoort, Handel, Summers, & Clements, 2014;
Talbot & Aronson, 2012, p. 376). Such study designs are notable for producing accurate
and useful results at detecting and verifying adverse events given exposures, particularly
rare drug/adverse event relationships, but may be susceptible to selection bias
(Backenroth, Chase, Friedman, & Wei, 2016; de Bie et al., 2015; Lanza et al., 2016;
Norén et al., 2013; Talbot & Aronson, 2012; Thygesen et al., 2017, p. 376). Cohort
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studies excel at detecting rare events (Pugh et al., 2014). However, it is important to point
out an important limitation: such study designs are not informative about risk factors,
enabling conditions, contraindications, and alternate etiologies that can help to explain
the nature of an alleged drug/adverse event relationship. Furthermore, in observational
data there is always the risk of unobserved and unmeasured covariates.
2.2.2 Control by Analysis
Control by analysis implies the application of statistical techniques to identify
covariates to control for confounding from data or background knowledge. One research
tack in confounding control in EHR-based pharmacovigilance has focused on using the
data to identify individual confounders (Backenroth et al., 2016; Y. Li et al., 2014). Li et
al. recently developed a method to identify confounders in data. Li used a propensity
score method (PSM) (Tatonetti, Ye, Daneshjou, & Altman, 2012) to identify factors
associated with the treatment and another technique to identify risk factors associated
with the outcome (R. Harpaz et al., 2012). An overlap between these two sets (of the
“comorbidity” subtype in pharmacovigilance) were collected. Li processed subsets of
these data-derived confounders using penalized regularization methods, specifically lasso
regression (Y. Li et al., 2014). Lasso regression is a regularization and variable selection
technique that shrinks multivariate predictor coefficients that fall beneath a threshold
down to zero (Tibshirani, 1996). However, Least Angle Regression (LAR), the algorithm
that is most commonly used to perform lasso regression, can be computationally
expensive, depending on input, being either quadratic 𝑶( 𝒏 𝟐 ) or cubic 𝑶( 𝒏 𝟑 ) in
its computational complexity. Recent innovations such as cyclic coordinate descent, have
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produced improvements in this regard (Efron, Hastie, Johnstone, & Tibshirani, 2004; J.
Friedman, Hastie, & Tibshirani, 2010; N. Simon, Friedman, Hastie, & Tibshirani, 2011).
Using these methods, Li reported a precision of 83.3% (95% CI: 62.2% to 100%)
for rhabdomyolysis and 60.8% (95% CI: 47.4% to 74.2%) for pancreatitis. These scores
improved upon scores and confidence intervals using either risk factors or PSM scores
alone. Li noted that having a sufficient number of samples is critical to decreasing the
number of false negatives, as many adverse events are rare.
2.2.2.1 Disproportionality Metrics
Disproportionality metrics are a traditional method of detecting drug/adverse
event relationships in SRSs. These include Odds Ratio, Reporting Odds Ratio (ROR),
and Reporting Risk Ratio (RRR). As these metrics are derived from the occurrence
statistics of pairs of entities (without addressing other [potentially confounding] entities),
these techniques were found to have little utility in terms of either sensitivity or
specificity for EHR data (DuMouchel, Ryan, Schuemie, & Madigan, 2013; Ryan, Stang,
et al., 2013).To account for sampling bias and differences between sample size, to
increase sensitivity to rarer adverse events, the Multi-item Gamma Poisson Shrinker
(MGPS) was developed and is currently in use by the United States Food and Drug
Administration (FDA) (Commissioner, n.d.; Rave Harpaz et al., 2013). Longitudinal
Gamma Poisson Shrinker (LGPS), a variation of MGPS, has been applied to claims and
EHR data (Schuemie, 2011; Zorych, Madigan, Ryan, & Bate, 2013). The inability of
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these methods to account for confounding has been cited as a limitation (Shrier & Pang,
2015).

2.2.2.2 Meta-analytic methods
Other innovative signal detection approaches have involved combining multiple
data sources (including at times “omics” data) via meta-analysis (Evans, Chaix,
Lobbedez, Verger, & Flahault, 2012; Y. Li, 2015; Oliveira et al., 2013; G. Trifiro et al.,
2014). Li was able to achieve 0.73 overall AUROC by combining EHR with FAERS data
(improving AUROC of the EHR by 0.22 from the overall baseline of 0.51) (Y. Li, 2015).
However, these techniques insofar as they apply to the detection of drug safety signals in
EHR belong arguably to a higher ontological order of pharmacovigilance – that of
substantiation and validation (Bauer-Mehren et al., 2012; Talbot & Aronson, 2012;
Gianluca Trifiro, Sultana, & Bate, 2018). Meta-analysis has the potential to improve the
performance of any individual method to the extent that it can be applied to multiple data
sources.
2.2.2.3 Other common methods
Other regression and regularization based methods have been applied to EHR
systems, including propensity scores – wherein the characteristics of a large set of
covariates is collated into a single score that measures the likelihood that a patient
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received a treatment (Rave Harpaz et al., 2015; Madigan, Ryan, & Schuemie, 2013;
Rosenbaum & Rubin, Donald, 1983). Ideally, the treated and untreated subgroups should
have similar characteristics. However, Ali et al. and Jackson report that the selection of
covariates that are used in studies that that use the PSM rarely report their covariates or
how they came to chose them (Ali et al., 2015; Jackson, Schmid, & Stuart, 2017).
There exist hybrid methods as well, e.g., recent research incorporating
confounders from enriched data (Backenroth et al., 2016). Data enrichment refers to the
utility of introducing relevant evidence to a problem of interest to contextualize and
understand it (Boyce et al., 2014).
The question remains: what is the best way to integrate these data, this
information, this knowledge? Associational studies using traditional statistics offer only
descriptions of data, yet a critical component of what science desires is a means to derive
insight into mechanisms and interrelationships. The next section describes work that has
the means to peer beyond the associational approach.
2.2.2.4 Causal inference methods
The objective of causal inference is to estimate the likelihood of one variable
producing a change in another under varying conditions and may be thought of as “the
counterpart to experiment” for observational data (Ranganath & Perotte, 2018).To date,
most work that has been done with causal inference methods in the field of
pharmacovigilance have been in application of instrumental variables (Brookhart,
Rassen, & Schneeweiss, 2010; Brookhart, Wang, Solomon, & Schneeweiss, 2006;
Davies, Smith, Windmeijer, & Martin, 2013). An instrumental variable is a variable that
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is chosen for fulfilling two criteria: 1.) it should not share a mutual cause with the
outcome (in this case, an adverse event), and hence is unconfounded with it; and 2.) it
should be correlated strongly with the explanatory variable, or estimator (in this case, a
drug) (S. Greenland, 2000).
An example of an instrumental variable that has been used in a pharmacovigilance
study would be the inclusion of a variable that represents the attending clinician, since
physicians may tend to be partial to the medications that they prescribe. However,
controversy exists over the validity of such variables (Brookhart et al., 2006). One metaanalysis of instrumental variable studies found that only 16/28 offered empirical evidence
that their choice of instrument fulfilled both criteria (Chen & Briesacher, 2011). Other
examples of instrumental variable types included patient history, financial status, and
calendar time. The intuition that underlies instrumental variables is that the instrument,
e.g., patient income, may be thought of as a “cue ball” in a game of billiards, where that
ball is struck by the player and is used strategically to propel other balls into the pockets
of the gaming table. If the instrumental cue ball is correlated with the outcome (the
adverse event), the causal effect of the candidate cause may be estimated with a simple
ordinary least squares regression (OLS) or two state least squares24 (Bowden &
Turkington, 1985; S. Greenland, 2000). Instrumental variables may be thought of as sidestepping the issue of identifying individual confounders, since instrumental variables may
be used to estimate effects “even in the presence of unmeasured common causes”
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OLS will work assuming that the dependency is linear.
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(confounders)25 (Chu, Scheines, & Spirtes, 2013). One recent exception to the focus on
instrumental variables in pharmacovigilance explicitly addresses the issue of
confounding, but the method described sidesteps the issue of identifying confounders by
inferring the magnitude of shared confounders between independent treatment regimes
and estimating upper and lower bounds for the influence of the latent (and unidentified)
confounders (Ranganath & Perotte, 2018).
The causal modeling techniques presented above excels in the case when there is
hidden latent and/or unmeasured confounding as no knowledge of covariates is required
and so the covariates it follows do not have to be measured26 (Ali et al., 2015). Indeed,
many of the methods that have been reviewed thus far are agnostic of covariates. What
happens if we have rich though flawed EHR data extracted from narrative text: a case in
which many individual confounders may have been measured? One promising source of
knowledge that may be exploited to identify potentially relevant covariates is the
literature.
2.4 Literature-Based Discovery
A fundamental limitation of the approaches mentioned above is that etiological insights
into confounders, risk factors, and enabling conditions that are present in the literature
may be amiss in the analyses of researchers. Absent the identification of exogenous
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Semi-instrumental variables wherein the non-confounding assumptions concerning the
outcome of interest are weakened may be used as estimators given that common causes
between the instrument and the outcome are controlled for and measured (Chu, Scheines, &
Spirtes, 2013).
26
Koller likens such methods to modelling a process of, to paraphrase, all latent background
stochastic processes (Koller, Friedman, & Bach, 2009).
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variables in observational data, researchers may not be able to take full advantage of
EHR data. Since EHR is so rich, might it be possible to identify confounders and control
for them in observational data so as to gain additional insight?
Traditionally, statisticians have depended upon the domain knowledge elicited
painstakingly from domain experts to identify relevant confounding factors (Y. Li et al.,
2014). While this approach to gathering background knowledge is likely to result in the
identification of confounding variable candidates pertinent to an individual study, it
would be financially intractable to hire the quantity and diversity of experts needed to
conduct pharmacovigilance across large numbers of marketed drugs and each of their
potential adverse events.
The focus of literature-based discovery has historically been on the identification
of novel therapies. Literature-based discovery methods have recently been utilized to
assess the plausibility of drug/adverse event associations (Cohen & Widdows, 2017;
Hristovski et al., 2006; Mower, Subramanian, Shang, & Cohen, 2016; Shang, Xu,
Rindflesch, & Cohen, 2014). As literature-based discovery has not traditionally been a
paradigm to interoperate with observational data, the current work represents a novel
problem domain for literature-based discovery methods, where such methods are
repurposed to identify confounders in observational data for adjustment.
2.5 Summary
The gap the current work addresses is the lack of methods tools to LBD-informed
causal modeling. The purpose of this work is to assess the extent to which feasibly sized
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sets of confounding variable candidates that have been observed in the literature can be
used to identify concepts that reflect this “causal story” for the task of confounding
adjustment of clinical data derived from EHR. The data-driven, knowledge-based method
described aims to find a middle ground between human-intensive expert-guided
confounding variable discovery and computationally intensive selection of such variables
based on empirical data alone. The following chapter provides an overview of literaturebased discovery methods of identifying such a causal story with which to populate
statistical and causal inference models.
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Chapter 3: Methodological Framework
This chapter explains the core components of the approach developed and tested in this
dissertation (causal modeling and literature-based discovery), and then provides
theoretical context to understand how these components complement each other.
Causal Modeling and Literature-based Discovery: a Synthesis. The method
developed uses the literature to identify contextually relevant variables to include in
statistical and/or causal models as a means to control for confounding bias in
observational clinical data derived from EHR. This chapter leaves out some specifics,
e.g., version of SemMedDB used, which Discovery Patterns, the advanced methods for
estimate the Average Treatment Effect (ATE) (described in Chapter 6). Such specific
details of the experiments will be described and clarified in the chapters to follow.
3.1 Overview of Causal Modeling
In recent decades, causal inference methods have been developed by such seminal figures
as Judea Pearl, Gregory Cooper, and Clark Glymour (Cooper, Gregory F., 1984; Judea
Pearl, 2009; P. Spirtes et al., 2012; Peter Spirtes & Glymour, 1991). The patrimony of the
field of causal modeling is remarkably diverse and interdisciplinary. The fields that have
contributed to causal inference include the following: its epistemological basis
(philosophy of science), potential outcomes framework and path diagrams (agronomy
and genetics) (“Corn and hog correlations / by Sewall Wright. v.1300(1925). - Full View
| HathiTrust Digital Library | HathiTrust Digital Library,” n.d.; Neyman, 1937; Neyman,
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Iwaszkiewicz, & Kolodziejczyk, 1935; Rubin, 1990; S, 1921), structural equation models
(economics and the social sciences) (A, 1990; “CFM 14 | Cowles Foundation for
Research in Economics,” n.d.; Duncan, 1975; Goldberger & Duncan, 1973; Haavelmo,
1944; J, 2008), counterfactual analysis (philosophy) (Cartwright, 2007; C. N. Glymour,
2001, 2001; Hume, 1740, 1748; Lewis, 1979; Mill, 1843; Scheines, Spirtes, Glymour,
Meek, & Richardson, 1998), computational tractability (computer science and cognitive
science) (Gabbay & Woods, 2005; Gopnik et al., 2004; Griffiths, Sobel, Tenenbaum, &
Gopnik, 2011; Griffiths & Tenenbaum, 2005; Holyoak & Cheng, 2011, 2011; Judea
Pearl, 2009). While an exhaustive review of the field is beyond the scope of the present
discourse, I will provide historical details when it may prove insightful or for
clarification.
The objectives of causal inference are manifold. One researcher may wish to specify the
data generating process responsible for a set of observations to understand the underlying
mechanisms. Another objective might be to provide insight into how to weigh policy
options or risk/benefit factors when considering an intervention, e.g., the effects of
raising the rate of interest on employment, or choosing between chemotherapy or surgery
(J. Pearl & Mackenzie, 2018; Judea Pearl, 2009). Exact causal inference has been shown
to be NP-hard27; however, causal inference from data may be approximated (Gavril,
1977; Heckerman et al., 1995; Koller, Friedman, & Bach, 2009; Marco Scutari, Vitolo, &
Tucker, 2018).
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The search space is super-exponential with the number N of nodes (N. Friedman, 2013).
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The causal graphs (also referred to as “causal Bayesian networks”) and the potential
outcomes (also referred to as the counterfactual intervention) framework have been
synthesized into a coherent discourse only in the recent past several decades28 (M.A.
Hernan & Robins, 2017; Morgan & Winship, 2015; J. Pearl & Mackenzie, 2018; Judea
Pearl, 2009). Researchers realized that causal graphs and counterfactual approaches are
essentially different languages for emphasizing and expressing aspects of the same core
underlying ideas, with each suited for the sub-tasks for which they were initially devised
(Morgan & Winship, 2015; J. Pearl & Mackenzie, 2018; Judea Pearl, 2009). These core
tasks of causal modeling are the following: inferring causal graph structures (qualitatively
determining which variables influence each other), quantitatively estimating relative
strength of such relationships encoded in the graph, and predicting how the variables
subsumed in such models might behave under perturbation.
Causal inference requires additional assumptions (although these can be
tempered): faithfulness, the causal Markov condition, and absence of latent confounders
(the latter will be defined and explained in the next section). Faithfulness assumes that
the causal graph represents valid dependency or causal relationships (J. Ramsey, Zhang,
& Spirtes, 2012; Uhler, Raskutti, Bühlmann, & Yu, 2013; Zhang & Spirtes, 2012). The
causal Markov condition describes how parent nodes in a DAG define child nodes. The
intuition behind this is that sans quantum entanglement or “spooky action at a distance,”
causal relations tend to be spatially and temporally contiguous. Finally, there is the
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Contention remains about whether or not these two frameworks have been reconciled, however. At there
remain two camps: those who use graph search vs. the potential outcomes (where the predictor and an
outcome variable are pre-specified). In this dissertation, both approaches are used.
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assumption of the absence of latent confounding29. That is to say that it is assumed that
the model includes all relevant mutual causes and influences. Other perils exist for the
would-be causal modeler: for example, selecting confounders that are themselves
confounded, and “over-controlling” for confounding (Elwert & Winship, 2014; M.A.
Hernan & Robins, 2017; Morgan & Winship, 2015; Judea Pearl, 2009).
Structure Learning. There are two main algorithm classes for identifying
graphical structures that are compatible with input data. These are constraint-based and
score-based learning algorithms. Constraint-based learning entails a search for
dependency relationships between input data representing nodes in a graph. If two nodes
are independent (their correlation falls beneath a threshold), then no edge is detected
between them (correlation is a necessary but insufficient pre-condition for a causal edge).
The most famous constraint-based causal structure learning algorithm is the “PC”
algorithm, first developed by Peter Spirtes and Clark Glymour (Peter Spirtes & Glymour,
1991). Another is the Fast Causal Inference (FCI) algorithm (Scheines et al., 1998; Peter
Spirtes & Zhang, 2016; Zhang, 2008).
Score-based algorithms on the other hand stochastically add, delete, orient edges,
and optimize for a fitness criterion, e.g., Bayesian Information Criterion, wherein the loss
function is minimized between the model and the data. Examples of these include the
Fast Greedy Equivalency Search (FGeS) algorithm (J. D. Ramsey, 2015), derivative of
Chickering and Meek (Chickering, 2015). Score-based algorithms are typically more
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This assumption is often weakened or qualified as algorithms exist specifically to detect hidden latent
confounding in the data, e.g. Greedy Fast Causal Inference (GFCI) and Fast Causal Inference (FCI) .
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efficient than those which are constraint-based since they do not perform an exhaustive
search. While score-based methods excel in computational efficiency and are easily
parallelized, they are often poor at detecting latent variables (J. D. Ramsey & Malinsky,
2016; Zhang & Spirtes, 2012). Hybrid structure learning algorithms exist as well. Most
notable among these would be Greedy Fast Causal Inference (GFCI), which first runs
FGeS and then prunes edges with a constraint-based structure learning algorithm
(Ogarrio, Spirtes, & Ramsey, 2016; J. D. Ramsey & Malinsky, 2016; TETRAD, 2017).
Parameter estimation and the quantification of estimated treatment or causal effects are
addressed in Chapter 6.
The output of most score-based causal structure learning algorithms is a set of directed
graphs with the observed variables as vertices and is known as a completed partially
directed acyclic graph (also called a “pattern”), or CPDAG. A CPDAG describes a family
of graphs which are score-equivalent (Geiger, 1990; Ogarrio et al., 2016; Judea Pearl,
2009; P. L. Spirtes, 2013). That is, based on the input data, the structure learning
algorithm cannot specify a unique form of a graph as there may be latent variables (Chu
et al., 2013; Geiger, 1990; P. L. Spirtes, 2013). In the case of a CPDAG, this means that
some edges may be bi-directed. However, given domain knowledge, many of these edges
can be oriented. If a known confounder is introduced, for example, directed edges should
be oriented toward both the predictor or explanatory variable and the outcome. The next
subsection discusses how confounder variable candidates are identified in the literature.
3.2 Literature-Based Discovery
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Literature-based Discovery (LBD) is an idea first developed by Don Swanson as a means
of using the biomedical literature to investigate therapeutically useful associations
(Smalheiser, 2017; Swanson, 1988, 1989, 1989). Swanson's approach involves examining
latent relationships between concepts that may suggest undiscovered therapeutic
relationships. More recently, LBD researchers have explored the idea of using semantic
constraints to reduce the search space of relevant associations (Bruza & Weeber, 2008;
Hristovski et al., 2006). For example, the following discovery pattern describes a set of
semantic constraints with which to identify a set of concepts: "drug INHIBITS x; x
CAUSES disease." The variable “x,” referred to as a “bridging term,” may indicate a
confounding concept that is associated with a drug and an adverse event. An example of a
bridging term would be a term that appeared in Don Swanson’s original research in LBD:
Eicosapentaenoic acid, or EPA, an ingredient in fish oil. Swanson noticed that the
mechanisms that underlie the pathology of those who suffer from Raynaud disease are the
opposite of the changes that are produced by consuming fish oil, e.g., decreased vs.
increased blood viscosity (Swanson, 1986). In this way, Swanson was able to identify a
novel therapy for Raynaud’s disease and proceeded to identify other potential therapies
(Swanson, 1988, 1989). These patterns of relationships are known as “discovery
patterns” (Hristovski et al., 2006).
While discovery patterns have been used to identify therapeutic and harmful
relationships previously, their application to identify confounding variables for causal
and statistical models is unprecedented. Some means to traverse discovery patterns is
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required to make LBD scalable. The next section will address such computational
considerations.
3.2.1 Predication-Based Semantic Indexing (PSI)
Recent work in the area of discovery pattern-based LBD has leveraged high-dimensional
vector space representations derived from large (tens of millions) repositories of conceptby-predicate-by-concept triples30 (known as semantic predications – e.g., x INHIBITS y)
to facilitate efficient search and accurate inference, using a technique called Predicationbased Semantic Indexing (PSI) (Cohen, Schvaneveldt, & Rindflesch, 2009; Cohen,
Widdows, Schvaneveldt, Davies, & Rindflesch, 2012). Vector Space Architecture (VSA)
theory provides the infrastructure for PSI (Gayler, 2004; Levy & Gayler, 2008). After the
imposition of a reversible vector transformation to encode the nature of a relationship
connecting two concepts, these elemental vectors can be superposed upon each other to
generate composite semantic structures called semantic vectors (Cohen et al., 2009;
Cohen, Schvaneveldt, & Widdows, 2010; Cohen, Whitfield, Schvaneveldt, Mukund, &
Rindflesch, 2010; Cohen, Widdows, Schvaneveldt, & Rindflesch, n.d.; Kanerva,
Kristoferson, & Holst, 2000; Widdows & Cohen, 2015).
3.2.2 PSI and for identifying confounding variable candidates
PSI uses random vectors. These random vectors are an effective way to represent
elemental components, since there is a high probability of mutual near-orthogonality in

30

Predications are relationships in which pairs of concepts are connected by predicates (or “verbs”, e.g.,
“TREATS”, “CAUSES”, “INHIBITS”, “STIMULATES”) in biomedical literature.
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higher dimensions. Semantic vectors, on the other hand, are composed as superpositions
of the “bound products” of the aforementioned elemental vectors of predicate-argument
pairs (as extracted from the literature using SemRep) (Kanerva, 1994; Kanerva et al.,
2000). The binding operator, which varies in implementation across VSAs, is a
multiplication-like operator that provides the means to encode additional information,
such as the nature and context of a relationship, into the resulting vector space. Since the
same predication can be encountered in multiple documents, PSI can be thought of as a
distributional model of predications. Critical to PSI, semantic representations of concepts
are built up as vectors from relations found in the literature. PSI facilitates the rapid
search for, and retrieval of, concepts that are related to one another in particular ways
(i.e., through particular predicates). As such a space is distributional, concepts in which a
relationship of interest occur more frequently will be retrieved first (analogous to the way
in which other information retrieval systems facilitate ranked results). In the current
work, PSI is used to facilitate rapid retrieval of concepts related to other concepts along
discovery patterns that suggest potential confounders. PSI can be used to retrieve the
most strongly associated concepts (called “bridging terms”) across any particular
predicate discovery pattern of interest and even identify novel discovery patterns
themselves (Cohen et al., 2012). A discussion of predicate discovery patterns that
indicate discovery patterns will follow. PSI and its other applications are discussed in
detail elsewhere (Cohen, Schvaneveldt, et al., 2010, 2010; Cohen et al., 2012; Widdows
& Cohen, 2015).
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The operative assumption is that if plausible therapeutic relationships in a
knowledge base of biomedical literature (which has arguably been the primary focus of
work in LBD to date), then semantic constraints may be used to identify common causes
and exploit the common cause principle. Since LBD uses distributional semantics, such
concepts that are identified in the literature may be predictive of entities that tend to cooccur with drug/adverse event pairs of interest in observational clinical data.
Confounding variable candidates may be identified by matching the pre-defined
relationship-types encoded by discovery patterns. In the next section the question of how
the structure suggested by discovery patterns can inform the construction of causal graphs
instantiated with EHR data.
3.3 Framework for LBD-informed Statistical and Causal Modeling
This section discusses how literature-derived confounding variable candidates may be
incorporated into predictive (statistical or causal) models.
3.3.1 LBD-informed Statistical Modeling
As there is no structure in statistical modeling, the integration of literature-derived
covariates is simple. Once a set of covariates has been chosen, a model and a regression
coefficient may be extracted for further processing.
Domain knowledge extracted from the literature assists in the automated construction of
statistical models in at least two ways:
1. By identifying relevant covariates informed by semantic constraints, the input
may be supplied for processing by statistical methods;
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2. Given semantic constraints of the literature-derived confounders, this reduces the
computational requirements when using a regularization method (ridge or lasso
regression) to reduce the set of covariates.
3.3.2 LBD-informed Causal Modeling
Causal inference requires some means to automate the process of identifying contextually
relevant covariates (feature selection) to scale. Domain knowledge extracted from the
literature assists in the automated construction of causal models in three ways:
1. By identifying relevant covariates informed by semantic constraints, the causal
graphs are populated with nodes/covariates;
2. Given semantic constraints of the literature-derived confounders, the edges of the
graph can be oriented in the event of “data equivalence” of the learned graph
structure.
3.

Prior information concerning the orientation of graph edges helps
computationally to reduce the search space for learning the graph structure.

Once the structure has been learned, the relationship between nodes may be estimated.
So, LBD can provide contextually relevant domain knowledge to facilitate the
automation of causal modeling. This section will describe the methods that have been
developed to facilitate predictive modeling in pharmacovigilance.
Causal modeling for pharmacovigilance. Moving from these theoretical
considerations, I will describe how sets of such confounders can be identified for
inclusion into causal models for de-confounding observational clinical data derived from
EHR data.
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3.3.3 Methodological Overview and Evaluation Framework
The next subsections describe the process of constructing a causal knowledge base using
PSI and the steps for using this knowledge base to identify, validate, and include
literature-derived covariates in statistical and causal models.
3.3.3.1 Materials
This subsection introduces the data that will be used in a series of experiments for
evaluating the method. The data that one first receives are seldom in the shape that they
need to be for practical use. The next section describes how the raw data were collected
and processed into a representation amenable to downstream analysis.
EHR data. Clinical text derived from electronic health records is the primary
source of raw data for this dissertation. Data from structured fields were not included in
the analysis, only unstructured text. Unstructured text data is known to contain valuable
information that is not contained in structured data – this may include indications of
“temporal relations, severity and degree modifiers, causal connections, clinical
explanations, and rationale” (Johnson et al., 2008). The primary unit of analysis is the
individual electronic health record which represents a single, unique visit by a patient to a
clinician. EHR data was obtained after obtaining permission from the [UTHealth]
Internal Review Board (IRB). A corpus of approximately 2.2 million electronic health
records (EHR) was extracted from the UTHealth’s clinical data warehouse concerning
outpatient encounters for ~ 364,000 patients in the Houston metropolitan area between
2004-2012 (UTHealth BIG., 2017). MedLEE, a clinical Natural Language Processing
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system, was used to normalize concepts in the EHR corpus (C. Friedman, Shagina,
Lussier, & Hripcsak, 2004). MedLEE has been shown to perform accurately on clinical
notes, for example with a recall of 0.77, and precision of ~ 0.89 for the task of extracting
clinical concepts (C. Friedman et al., 2004). In addition to identifying concept types
("health outcomes of interest," "medications"), MedLEE also encodes each extracted
concept with a concept unique identifier (CUI) from the Unified Medical Language
System (UMLS) (A. R. Aronson, 2001; The Unified Medical Language System (UMLS).,
2017).
Next, for convenience, I indexed the MedLEE-process corpus of EHR data using Apache
Lucene31 to facilitate the extraction of document-level co-occurrence statistics. From this
index, document-by-concept arrays were obtained. A list of document ids specific to the
Lucene index was extracted for each UMLS CUI in the index. Next, each concept (drug,
adverse event, or adjustment set of confounders) was persisted as a large sparse binary
array and compressed. In these binary arrays (input for causal algorithms), a value of 1 or
0 represents presence or absence of that concept within a document in the corpus index.
These arrays are later used as input for statistical and causal algorithms. These matrices
can be constructed quickly, and can represent the observational data for each of the drugs,
adverse events, and their confounders, and can provide input matrices for the causal
methods to be described.

31

https://lucene.apache.org

44

Reference Dataset. Reference data sets are used for methodological evaluation in
pharmacovigilance. These datasets customarily consist of a number of
medication/adverse event pairs wherein there are cases (a causal relationship between
exposure and adverse event has been established) and controls (no known relationship).
A reference set of curated drug/adverse event associations that was developed by Ryan
and his colleagues as a standard for evaluating pharmacovigilance method was used for
methodological evaluation (Ryan, Schuemie, et al., 2013). This reference set includes 399
drug/adverse event pairs for four clinically important adverse events with both positive
(drug/adverse event relationships supported by the literature and other sources, including
package labeling events) and negative (drug/adverse event relationships without support)
control groups per adverse event. The four adverse events are as follows: acute kidney
injury (AKI), acute liver injury (ALI), gastrointestinal bleeding (GIB), and acute
myocardial infarction (MI). These adverse events were chosen for their importance to
pharmacovigilance and for their impact on financial and personal cost. I mapped and
expanded drug/adverse event synonyms to make the EHR data amenable to additional
processing. I used RxNorm for drug synonyms at the clinical drug level, and I assigned
the reference set’s Observational Medical Outcomes Partnership (OMOP)adverse event
to UMLS CUIs (Nelson, Zeng, Kilbourne, Powell, & Moore, 2011; Observational
Medical Outcomes Partnership (OMOP), 2017; RxNorm., 2017). For example, the
generic concept “Ibuprofen” is encoded with a CUI string of “C0020740,” while the
specific concept that refers to a brand-name instance of “Advil Ibuprofen Caplets” is
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“C0305170.” To gain statistical power, these CUIs are reconciled into a single
representation. Table 1 presents an overview of the reference dataset:
Table 1
Ryan et al. (2013) Reference Dataset
Adverse Events

Case

Control

Total

24

64

88

81

37

118

36

66

102

24

67

91

164

164

399

AKI (Acute Kidney
Injury)

ALI (Acute Liver
Injury)

AMI (Acute
Myocardial Infarction)

GIB (Gastrointestinal
Bleeding)

Total

Note. Categories in far left denote health outcomes of interest phenotypes in the OMOP
reference data set.
The next subsections discuss the confounding variable candidate discovery and validation
process.
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3.3.3 Confounding Variable Discovery Process
To construct a knowledge base for the present experiment, Predication-based Semantic
Indexing was supplied to SemMedDB, a knowledge repository developed by the National
Library of Medicine using SemRep (Cohen et al., 2009; Kilicoglu, Shin, Fiszman,
Rosemblat, & Rindflesch, 2012; SemMedDB, 2017). PSI uses random projections and
reversible vector transformations to derive distributed concept vector representations
from SemMedDB, mediating efficient but approximate search, retrieval, and inference.
The higher the dimensionality that is used, the better the recall and precision of the model
(with a trade-off of computational efficiency). When searching for the missing argument
of a predicate-argument pair, concepts that fill this role most frequently will be retrieved
first, analogous to the ranking of results in search engines. In the current work, PSI is
used to facilitate rapid retrieval and rank ordering of concepts related to other concepts
through particular predicates.
3.3.3.1 Querying PSI Spaces with Discovery Patterns to Identify Potential
Confounders
The Semantic Vectors package (Semantic Vectors, n.d.) provides an interface that
permits searching PSI spaces for concepts that populate particular predicate discovery
patterns, which I used to identify the most strongly associated confounders for each
drug/adverse event pair. If the following discovery pattern is used to identify
confounding variable candidates: “drug TREATS confounder; confounder CAUSESINV adverse_event,” given acarbose (used to treat diabetes mellitus) and myocardial
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infarction as cue terms, “metabolic disorder” will be obtained as one of the results. The
order in which these covariates are retrieved reflects their ranked relevance given the
distributional semantics of the query terms in the index. Sample confounders for
abacavir, an antiretroviral used to treat AIDS in the negative control group for
gastrointestinal bleeding, include (by ranked order of relevance): Dieulafoy’s vascular
malformation, HIV infections, lipoatrophy, HIV encephalopathy, and angiodysplasia.
Further down the list, confounders become less specific: peptic ulcers and diabetes. In the
evaluation, I excluded spurious associations (as all vectors in the space are a measurable
distance apart) from confounders, making use of a frequency threshold, such that only
bridging terms with association strengths 2.5 standard deviations were included. More
confounders from the discovery patterns that were used are included below in Table 2:
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Table 2
Discovery Patterns (“DPs”) for Statistical and Causal Modeling
Confounding
DPs
Type
X CAUSES adverse_event
X PREDISPOSES adverse_event

Example
Confounding Variable
Candidates32
drug:
allopurinol
adverse event: liver
failure

co-medication,
comorbidity

transplantation, embolism

co-medication,
comorbidity

transplantation, embolism
pericarditis, gout, kidney

drug TREATS X;
X COEXISTS_WITH adverse_event
drug TREATS X;
X CAUSES adverse_event

comorbidity

comorbidity

failure
hyperuricemia, gout

Note. Items are in far left and denote the discovery patterns used in the experiments. The
first three discovery patterns were used only in the first experiment (Chapter 5), whereas
the fourth discovery pattern was used in Chapter 5 (“graph structure”) and Chapter 6
(“using simulations to quantify average treatment/causal estimates”).

A browser interface called EpiphaNet has been developed for querying PSI-based
representation of SemMedDB using a query language with metavariables that specify
predicate vectors, elemental vectors, semantic vectors along with binding and

32

In previous research in causal modeling, Cheng refers to such covariates as “focal sets” (Cheng, n.d.).
Greenland et al. refer to confounding variable candidates as “potential confounders” (S. Greenland et al.,
1999). Pearl et al. refer to the “focal set” of “potential confounders” as the “causal story” (J. Pearl,
Glymour, & Jewell, 2016; J. Pearl & Mackenzie, 2018).

49

superposition operators (Cohen et al., 2009; Cohen, Schvaneveldt, et al., 2010; Cohen,
Whitfield, et al., 2010; Cohen et al., n.d.; Kanerva et al., 2000; Widdows & Cohen,
2015). PSI vector space model of SemMedDB may be queried to identify confounding
variable candidates for each drug/adverse event pair with PSI queries that represent
discovery patterns. The results of a query through EpiphaNet’s
(http://www.epiphanet.uth.tmc.edu) web interface are shown below in Figure 2:

Figure 2. Illustration of EpiphaNet query results. EpiphaNet query results for
rosiglitazone and myocardial infarction are depicted. Note that the direction of the arrows
for TREATS reflects the semantics of that predicate. In causal terms, the edge is oriented
in the opposite direction in the sense that the disease CAUSES the exposure to the drug.
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3.3.3.2 Individual validation of confounder candidates with EHR data
When applying machine learning algorithms, it is vital to perform feature selection as it
will reduce the number of variables that are used to construct the model (current
reference). Having variables that are irrelevant can hinder analysis by increasing the
processing time, reducing available resources, and often lowering the accuracy and
precision of models through the introduction of multicollinear covariates. The implication
of this is that in either statistical or causal models, each literature-derived confounder
must meet a series of constraints for inclusion into downstream predictive models. The
first constraint entails first determining that it has been measured in the EHR data, as this
is a prerequisite to both further validation and predictive modeling. Secondly, each
confounding variable candidate must be correlated with at least the outcome (Chapter 4 –
initial experiments), if not both the predictor and the outcome (Chapter 5 and Chapter 6).
Validation entails first determining that it has been measured in the EHR data. Secondly,
each confounding variable candidate must be correlated with at least the outcome
(Chapter 4), if not both the predictor and the outcome (Chapters 5 and Chapter 6). The
justification for excluding variables that are not correlated with both predictor and
outcome is that such covariates fail to meet the criteria as confounders and so to be of
potential use in de-confounding observational data.
3.4 Summary and Roadmap for following chapters
In this chapter, I have sketched an outline of the framework that I have developed for
identifying confounders using the literature and integrating these into statistical and
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causal models. I will further develop and refine these ideas given the course of iterations
and refinements in the chapters that follow. Additional details concerning the data and/or
methods are specified in those respective sections of the forthcoming chapters. The items
enumerated below provide an outline of the general steps that hold across the
experiments to be described in detail in the forthcoming chapters.
1. Extract, process, and persist observational clinical data from the clinical data
warehouse (after obtaining approval from the [UTHealth] IRB.
2. Construct knowledge base of domain knowledge extracted from the literature.
3. Apply or research relevant synonym mappings for medications and adverse events
from a publicly available reference dataset to be used for methodological evaluation.
4. Evaluate baseline performance of EHR data for pharmacovigilance signal detection
using desired method (odds ratio, logistic regression) without confounding adjustment
by calculating the area under the curve of the receiver operator characteristic curve
using baseline scores for each drug/adverse event pair in the respective reference
dataset.
5. Query the knowledge base for contextually relevant confounders using each
drug/adverse event in the reference dataset as cue terms, given a discovery pattern,
and determine if the literature-derived covariate behaves like a “confounder.”
6. Construct statistical and/or causal models by incorporating the verified confounders.
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7. Evaluate confounder adjusted performance of EHR data for pharmacovigilance
signal detection using desired method (odds ratio, logistic regression) without
confounding adjustment by calculating the area under the curve of the receiver
operator characteristic curve using adjusted scores (parameter metrics, regression
coefficients) for each drug/adverse event pair in the reference dataset.
If the pre-processing procedures may be abstracted out, since these have been completed
by the time individual experiments begin, the steps above may be reduced to those
illustrated in Figure 3 below:

Figure 3. Illustration of LBD-informed causal modeling framework. This illustration
represents the study design of the method and experiments. Each experiment can be
thought of a “variation on a theme”: the particular elements may vary (reference data set,
the provenance of clinical data, modeling class [statistical or causal] or algorithm), but
the overall workflow remains consistent across the experiments.

53

Variations on Figure 3 will be revisited and adapted for the experiments presented in the
chapters that follow. Individual elements concerning implementation details will vary
(statistical vs. causal modeling, discovery pattern), but the overall workflow will be
consistent.
Roadmap for the forthcoming chapters. Chapter 4 describes an experiment
wherein I integrated literature-derived confounders into statistical models using stepforward logistic regression and three “discovery patterns”. Chapter 5 presents an
experiment where I used combinatorial permutation upon sets of literature-derived
confounders as a scoring mechanism using a discovery pattern that identifies comorbidity-type confounders with a “drug TREATS x; x CAUSES adverse_event” dual
predicate discovery pattern. Chapter 6 describes and evaluates a method to obtain
estimates of the average treatment effect of the likelihood of medications to cause
adverse events, using the same discovery pattern from Chapter 5. Finally, Chapter 7
presents the accomplishments, contributions, limitations, and possible directions for
forthcoming work in detail.
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Chapter 4: Using the Literature to De-confound Statistical Models
The material in this chapter was presented at AMIA Symposium 2016, Chicago, IL:
Malec, S. A., Wei, P., Xu, H., Bernstam, E. V., Myneni, S., & Cohen, T. (2016).
Literature-Based Discovery of Confounding in Observational Clinical
Data. AMIA Annual Symposium Proceedings, 2016, 1920–1929.
This chapter constitutes the initial exploratory analysis of LBD-informed
predictive modeling. As can be expected from an exploratory analysis, the
methods and concomitant results presented are as yet in their infancy. LBD
techniques are used to cast a wide net to identify intervening variables. Initially,
any sort of intervening variable will do (confounder, mediators, alternate
etiologies33). These intervening variables must meet at least two criteria in order
to be considered for inclusion in statistical models: 1.) they must be
mechanistically related to at least the health outcome (adverse event) in the
literature through pre-defined relationships (“discovery patterns”); and 2.) they
must be correlated with both (predictor and outcome) in the EHR data. The
objective of this study was to see which discovery pattern or type of intervening
variable would work the best (or at all) for improving the quality of
pharmacovigilance signals in EHR data. Critical lessons were learned and

33

The broadness of this initial motivation does not fit with the exclusive focus on confounders, but at the
conclusion establishes this focus, preparing the way for the next two chapters/experiments, where the focus
is exclusively on confounders from the outset.
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ideas evolved quickly from this initial conception, as shall be seen in the next
two chapters.
4.1 Introduction
The hypothesis evaluated in this chapter is that statistical models, adjusted with
literature-derived covariates, will more accurately identify causative drug/adverse event
relationships than baseline unadjusted models. In this experiment, intervening variable
candidates (hereon to be referred to as confounding variable candidates, or confounding
variable candidates) from three discovery patterns are integrated into statistical models
using forward stepwise logistic regression, and their capacity to de-confound
drug/adverse event signal in EHR data (from the UTHealth clinical data repository
(UTHealth BIG., 2017)) is evaluated using the OMOP reference dataset for
pharmacovigilance (Ryan, Schuemie, et al., 2013). EHR data and the reference dataset
were pre-processed as described in section 3.3.2 of the previous chapter.
Definitions. A confounding variable influences or biases the magnitude of the
correlation between a predictor variable (e.g., drug exposure/treatment) and a response
variable (i.e., outcome/adverse event). In the context of creating models for
pharmacovigilance, when a confounding relationship exists between a falsely associated
drug/adverse event pair and adjustments are made to account for its influence, the
association strength for that relationship should be diminished. For example, given a set
of observational clinical notes, it is observed that fish oil intake is highly correlated with
acute liver injury (ALI). However, after adjusting the model for the presence of known
causal agents of ALI, (e.g., acetaminophen, liver cirrhosis, hepatitis c), that correlation
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should approach zero. Let us consider another example of an acetaminophen exposure
(predictor) and a hepatitis B infection (predictor) where the patient subsequently suffers
ALI (response). In this case, each of these predictors, independently, are sufficient
preconditions for ALI. As they occur together, these two predictors may confound each
other. When the association of either predictor is adjusted in the absence of the other
predictor, the association may diminish, but not as dramatically as in the first example. Li
et al. introduced a taxonomy of confounding in pharmacovigilance with the following
categories: confounding by indication (e.g., preexisting conditions), confounding by
comorbidity (e.g., diabetes), and confounding by co-medication (e.g., aspirin) (Y. Li et
al., 2014; Talbot & Aronson, 2012).
A mediating variable, by contrast, lies distinctly along the causal discovery
pattern between the predictor variable and the response variable themselves and may be
neither necessary nor sufficient to cause an adverse event by itself. Mediators may
sometimes be thought of as “risk factors” or as aspects of the etiology of the adverse
event itself (Richiardi, Bellocco, & Zugna, 2013; Valente, Pelham, Smyth, &
MacKinnon, 2017). Examples of mediators include bile duct obstruction for (acute liver
injury/failure) ALI or hypertension for myocardial infarction (MI). For a more detailed
discussion of mediation, see (Judea Pearl, 2009; Richiardi et al., 2013; Tchetgen
Tchetgen & Vanderweele, 2014; T. VanderWeele, 2015; T. J. VanderWeele, 2012).
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4.2 Materials and Methods
Knowledge Base. A PSI vector space derived from version 24_32 of SemMedDB
(processed with version 1.5 of SemRep), containing 23.9 million citations and 70.4
million semantic predications (SemMedDB, n.d.) was used to construct a knowledge base.
A knowledge base consists of assertions of an etiological nature derived from the
literature. In this case, this knowledge base will be used to identify sets of covariates that
may be pertinent to an evaluation of putative drug/adverse event relationships of interest.
A 48,000-dimensional binary vector PSI space was built using the Semantic Vectors
package (version 5.9) (Semantic Vectors, n.d.). Predicates were excluded that indicate
negation (e.g., DOES_NOT_TREAT), as well as terms (“stop words”) with occurrence
≥ 500,000.
Derivation of confounding variable candidates from the literature. The
discovery patterns used in this chapter’s experiment are presented and summarized in
Table 3 below. These discovery patterns were identified while studying how domain
experts used of the EpiphaNet LBD interface to interpret results of drug/adverse event
queries. EpiphaNet would at times generate reasoning discovery patterns that suggest
confounding relationships. Note that “drug TREATS x; x COEXISTS_WITH
adverse_event” is referred to as a “double predicate” discovery pattern in that it is
composed of two predicates that yield confounding variable candidates that link to both
the drug/adverse event cue terms.
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Table 3
Discovery Patterns (“DPs”) for Statistical Modeling
DPs

Confounding Type

X CAUSES adverse_event
X PREDISPOSES adverse_event

Examples
drug:
allopurinol
adverse event: liver
failure

co-medication,
comorbidity

transplantation, embolism

co-medication,
comorbidity

transplantation, embolism
pericarditis, gout, kidney

drug TREATS X;
X COEXISTS_WITH adverse_event

comorbidity

failure

Note. Categories in far left in bold denote the discovery patterns used in this experiment.

Methods
Preprocessing steps for the data and knowledge base were described previously in
Chapter 3. Note that the input consists of document level concept occurrence statistics for
drugs, adverse events, and literature-derived covariates for statistical models.
Establish baseline performance by calculating the area under the curve from the
receiver operator characteristic34 (AUROC) curves from ranked-order of coefficients
from unadjusted logistic regression models.

34

AUROC is a popular metric used to summarize the performance of binary classifiers in statistical
machine learning, and calculated as area under the Receiver Operating Characteristic curve (from
sensitivity/1-specificity).
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1. Query PSI vector space for confounding variable candidates given each
drug/adverse event pair for confounding variable candidates and extract data from
the index. Fifty confounding variable candidates were extracted for each pattern
per drug/adverse event pair. The constraint for the inclusion of a confounding
variable candidate into a statistical model is at least ten co-occurrences given the
EHR data for both the drug and the adverse event.
2. Construct confounding variable candidate-adjusted statistical models using
forward stepwise logistic regression and calculate the aggregated performance
statistics with AUROC. The statistical models are constructed in descending order
of co-occurrence count between drug, adverse event, and confounding variable
candidate concepts (with an intersection threshold of ten) for inclusion in the
statistical models. AUROC is calculated using the ground truth in the OMOP
reference data set (Ryan, Schuemie, et al., 2013) and the ranked ordering of the
regression coefficients from the generalized linear models of the drug/adverse
event pairs.
In the course of building models iteratively in step 3 above, when the statistical
model achieve a fit with a newly incorporated literature-derived covariate, that covariate
is incorporated into subsequent models. Confounding variable candidates that are
collinear with the exposure/drug and the adverse event may result in models that fail to
converge, or achieve a fit. This process continues for each drug/adverse event pair until
confounding variable candidates are exhausted for that discovery pattern. When such
models fail to achieve convergence, the offending concept is added to a list of exclusions
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for that pair so that it will not be included in subsequent builds, and it is retained for
manual investigation for interesting patterns. If none of the models for a drug/adverse
event pair converge using confounding variable candidates, then the score from the
unadjusted, or baseline, logistic regression coefficient is used to calculate AUROC. The
data analysis methods used in the current experiment are as follows both in the text and in
Figure 4 below:

Figure 4. Illustration of LBD framework for statistical modeling. EHR data derived from
the UTHealth clinical data warehouse was used as primary input and to test the literaturederived covariates. Literature-derived confounders from three discovery patterns will be
included in statistical models of EHR data using forward stepwise logistic regression:
CAUSES, PREDISPOSES, and “drug TREATS x; x COEXISTS_WITH
adverse_event”.
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4.3 Results
Table 4
Results for LBD-informed Statistical Modeling

AEs

DPs

AKI

Caus

Complete Results
Counts +/- Baseline Adjusted

Constrained Results
Counts +/- Baseline Adjusted

0.5853

11/13

0.6573

0.6643

0.584

NA

NA

NA

Tcoe

0.6126

NA

0.6972

0.6125

Caus

0.515

44/14

0.5536

0.5568

0.5297

50/24

0.4992

0.4825

Tcoe

0.492

58/25

0.509

0.5303

AMI Caus

0.5158

24/41

0.6026

0.6148

0.5196

30/47

0.5319

0.5574

Tcoe

0.5032

27/45

0.5687

0.5835

Caus

0.6418

20/48

0.6073

0.5792

0.699

20/49

0.5949

0.6571

0.7189

20/50

0.5964

0.69

Pred

ALI

Pred

Pred

GIB

Pred
Tcoe

24 / 64

81/37

36/66

24/67

0.5547

0.4957

0.5112

0.5643

Note. Categories in far left denote adverse events adverse events (AE) in the OMOP
reference data set. The next column denote discovery patterns. This table presents the
baseline and adjusted AUROCs that were calculated from the ranked order of logistic
regression models from each adverse event and discovery pattern combination. Caus = ”x
CAUSES AE,” Pred = ”x PREDISPOSES AE,” Tcoe = ”drug TREATS x; x
COEXISTS_WITH AE.” Counts = number of positive/negative examples. AUROCs in
bold indicate that an adjusted model drug coefficient is higher than baseline.
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There are two groupings of result data in Table 4, labeled Complete Results and
Constrained Results. Complete Results indicates that the AUROCs have been calculated
from the full data set without imposing any additional criteria.
In the Constrained Results, the following criteria were applied to calculate
performance metrics values for each field per adverse event/discovery pattern row such
that:
1.) All logistic regression models must have converged35.
2.) The count for drug instances was ≥ 100 in the EHR data.
3.) The count for intersections was ≥ 10 between drug/adverse event pair.
4.) The calculations derive exclusively from cases where confounding variable
candidates were included in the logistic regression models.
As a result, the count of positive and negative controls for the same adverse event will
vary, since confounding variable candidates differ between discovery patterns.
Observations. There were ~55,000 instances in the EHR index for each of ALI,
AMI, and GIB. AKI was the outlier with only ~5,000 instances. In the case of AKI for
the “x PREDISPOSES adverse_event” discovery pattern, no co-occurring confounding
variable candidates were identified so that no adjustment could be made. In the case of
ALI, one might reason that the set is heavily weighted toward the positive examples, so
little gain is to be had by adjusting with confounding variable candidates.

35

Some covariates are colinear with predictor, outcome, or both causing perfect or quasi-perfect
separation. This results in failure of convergence.
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4.4 Discussion
Analysis of Constrained Results. In the Constrained Results, for models that
include confounding variable candidate adjustments, performance improved in 8 of
eleven cases. The “drug TREATS x; x COEXISTS_WITH adverse_event” discovery
pattern improved performance in three or four cases, while the same can be said in two of
four “x PREDISPOSES adverse_event.” In only one case, AKI there was an
improvement using the “x CAUSES adverse_event” discovery pattern36.
Li et al. recently developed a data-driven confounding variable discovery method
using a propensity score method (PSM) (Jackson et al., 2017; Rosenbaum & Rubin,
Donald, 1983; Tatonetti et al., 2012) to identify factors associated with the treatment and
another technique to identify factors associated with the outcomes (R. Harpaz et al.,
2012) – in this case, rhabdomyolysis and pancreatitis. Overlaps between these two sets
(of the “comorbidity” subtype in pharmacovigilance) were collected and processed using
penalized regularization methods, specifically lasso regression (Y. Li et al., 2014). The
results are not strictly comparable with this study as the input data and drug/adverse event
pairs are different, but the best improvement was with the method above compared with
only the PSM or risk factor scores, and when there were a sufficient number of
exposures: at least 100. In another study in purely EHR-based pharmacovigilance, Li

36

The “x CAUSES adverse_event” discovery pattern is an intriguing start, however. It will be re-deployed
as the more reliable half of a dual predicate discovery pattern and figure prominently in discussions of later
chapters.
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combined FAERS with EHR data to obtain a 0.22 improvement in AUROC – from 0.51
to 0.73 (Y. Li, 2015).
Error Analysis. While it makes sense to use the single predicate
discovery patterns that imply causation or risk factors, e.g., “x CAUSES adverse_event,”
“x PREDISPOSES adverse_event,” respectively, concerning their ostensible causal
association for adjusting negative controls, the results of my analysis did not support this
intuition. Such discovery patterns uncover concepts that exist in the gray area between
mediators, risk factors (Pearl’s “indirect effects” predictors), and concepts which could
manifest confounding effects, e.g., smoking with respect to a positive control drug and
AMI (Judea Pearl, 2009). For example, the following cases of mediatorlike confounding
variable candidates from this discovery pattern were identified: stenosis, obstruction,
thrombosis, and thrombus. Such concepts are suggestive of mediating concepts that relate
to the causal mechanisms for AMI. Since mediators tend to be collinear with response
variables, inclusion of such confounding variable candidates may be detrimental to
performance (although means to correct for bias from such variables have been
developed and have been explored at length elsewhere) (Aalen, Roysland, Gran, &
Ledergerber, 2012; Richiardi et al., 2013; T. J. VanderWeele, 2012; Vanderweele,
Vansteelandt, & Robins, 2014).
Wordclouds. I have generated word clouds below in Figure 5. The purpose of
these wordclouds is to present examples of the types of concepts that were identified by
LBD. The wordclouds were generated using R’s wordcloud library (Fellows, 2014). The
wordclouds are generated from the processing of EHR data. The size of a word in each
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wordcloud indicates the prevalence of the concept. The first two wordclouds represent
the confounding variable candidates of ALI, and GIB with the “x CAUSES
adverse_event” discovery pattern. The third and fourth show the confounding variable
candidates for the AMI groups using the “x CAUSES adverse_event” discovery pattern.
The fifth word cloud represents the confounding variable candidates that were excluded
when building the logistic models for GIB using “drug TREATS x; x
COEXISTS_WITH adverse_event” discovery pattern. These literature-derived
confounding variable candidates were identified in the literature, but failed to meet the
inclusion criteria in the EHR data. The reader will notice that confounding variable
candidates from single predicate discovery patterns (e.g., “x CAUSES adverse_event”)
that were associated only with the adverse event were of both the comorbidity and comedication confounding subtypes, whereas confounding variable candidates from “drug
TREATS x; x COEXISTS_WITH adverse_event” are constituted exclusively by
comorbidities. The fourth word cloud (bottom row, left) is interesting in that the most
prevalent confounding variable candidates are comorbidities and likely mediators of
myocardial infarction.
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Figure 5. Illustration of Wordclouds from statistical modeling discovery patterns.
These word clouds represent confounding variable candidates for adverse events and
discovery patterns with font size proportional to aggregated term frequency (across all
drugs for a group [positive or negative control] of a given an adverse event and a
discovery pattern) in the EHR index.
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One perplexing confounding variable candidate from “drug TREATS x; x
COEXISTS_WITH adverse_event” discovery pattern for acute myocardial infarction is
fibroid tumor. Fibroid tumors of the gastrointestinal tract are relatively rare and usually
appear on the uterus. However, review of the predication database suggested that at times
anti-inflammatory agents may occur in TREATS relationships with fibroid tumors, as
they are used to control the pain associated with this condition. Though the “drug
TREATS x; x COEXISTS_WITH adverse_event” discovery pattern is intended to
retrieve terms that are associated with both the drug and the adverse event, the underlying
implementation involves vector superposition. Although I would anticipate terms that are
bilaterally connected being retrieved first, terms that are unilaterally connected may still
meet the threshold. Such spurious confounding variable candidates could be eliminated
by using a higher threshold of associational strength than the 2.5 standard deviation level
and by making a bilateral connection a prerequisite for retrieval37.
Conclusion. With the aim of surmounting the obstacle of confounding, a
phenomenon which diminishes the validity of information that can be extracted from
observational data, I have proposed a scalable and computationally inexpensive LBDbased confounding variable discovery method. The evaluation shows that when there is
sufficient support above random for an adverse event, i.e., AUROC 0.6, statistical models

37

Recall that there is a multi-stage filtration of confounding variable candidates. First the confounding
variable candidates must meet the distributional requirements in the PSI space. In vector space everything
is connected, so concepts that are retrieved must score above 2.5 standard deviations as noted to be
retrieved. Secondly, the confounding variable candidate that is identified with a score above the
distributional threshold must meet additional requirements: they must be measured/recorded and those
values must overlap at minimum ten times with both the predictor and outcome variables. Finally,
confounding variable candidates cannot be colinear with the predictor and outcome variables as this will
prevent the statistical models from converging (“perfect separation”).
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that incorporate adjustments for the influence of dual-predicate discovery pattern-derived
confounding variable candidates exhibit modest (0.05 AUROC or higher) performance
gains for the task of re-identifying drug/adverse event pairs from observational clinical
data.
This study had several limitations. These include:
1.) The discovery patterns that were used may not have identified “true”
confounders or mutual causes, but “alternate etiologies” and “mediators.”
a. An “alternate etiology” is another causal explanation for why
something occurred, and it may be independent of the explanatory
variable. It may not be useful for disentangling spurious associations
due to statistical correlation.
b. Like confounders, mediators are another type of intervening variable
between a predictor variable p and an outcome of interest o. However,
whereas a confounder C will betray this pattern: p Ü C Þ o, a
mediator M will have this pattern: p Þ M Þ o.
2.) The best performing discovery pattern was a dual predicate discovery pattern.
While the TREATS predicate offers strong evidence from the literature that
the co-morbidity bridging term may be responsible for causing or increasing
the likelihood of the exposure, the COEXISTS_WITH predicate does not
provide a strong indication that its object is viable mechanistically, but it is
associated by non-causal means. While such confounders may not be true
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confounders, they do offer clues as to how strong confounding variable
candidates might be identified.
The main lesson learned from this study is that dual predicate discovery
patterns are powerful tools for identifying useful confounding variable
candidates. In thinking about how the two types of intervening variables
relate to each other (mediator and confounder), confounders of the mutual
cause type were more easily understood and they performed better in the
aggregate. This indicated the direction to proceed.
The next two studies expand upon the LBD component of this initial
analysis and explore a more precise definition of confounder that was only
hinted at in this chapter. However, mediators will make a return (albeit in
refined form) in the discussion of future research in the final chapter, as
mediators turn out to be vital components of future directions of research in
LBD-informed modeling of EHR data.
The research that follows attempts to transcend associational methods. In
the next chapter, an experiment is presented that explores ways in which
asymmetric direction of influence inherent in causal predications can be
leveraged in causal directed acyclic graphs instantiated with EHR data.
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Chapter 5: Ars Combinatoria with Focal Sets of Potential Confounders
The material in this chapter was presented at the DMMI Workshop, part of the AMIA
Symposium 2017 held in Washington D.C.:
Malec, S., Gottlieb, A., Bernstam, E., & Cohen, T. (2018). Using the Literature to
Construct Causal Models for Pharmacovigilance. https://doi.org/10.29007/3rfr

In the previous chapter, the interpretation of an intervening variable was left
quite open: it could either be a mediator or a confounder. Moving from “mere
association” of logistic regression models, the experiment described below
explores intervening variables more precisely. Specifically, the thought behind
what the definition is and individual confounders behave or can be expected to
behave collectively and individually become more precise and nuanced. This
chapter introduces a new method to validate confounding variable candidates
using the directionality inherent in the semantic predications, since graph
structures with instantiated nodes, i.e., populated with values from the EHR
data, must be compatible with those data.
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5.1 Introduction
There can be said to be two distinct but related types of information encoded in
causal graphs: qualitative38 and quantitative. The qualitative aspect is more apparent: this
may be readily ascertained by the presence or absence of directed edges, characterized as
pointing in one or in the opposite direction. If a causal edge is present, influence will flow
in the direction in which that edge is pointing and produce and increase (or prevent and
decrease) the likelihood of the entity that is on the other side to occur. The other aspect is
quantitative – this is the problem of estimating the magnitude of the strength of that edge,
i.e., the “structural coefficient.”
In the experiment described in this chapter, the focus is on the qualitative
detection of edges in the graph topology learned by causal discovery algorithms and
imputed by causal propositions (predications) mapped from the literature. The operative
hypothesis is that the presence of sets of literature-derived confounding variables (hereon
to be referred to as “focal sets” of confounding variable candidates after Cheng (Cheng,
n.d.; Cheng & Novick, 1990)) will diminish the detection of spurious drug/adverse event
dependencies as encoded in graph structure in the aggregate.
However, since an AUROC cannot be calculated with binary values (the
qualitative aspect of graphs mean that an edge is either absent or present), a means to

38

Qualities are conceived as discrete, binary-valued: one either possesses an attribute or one does not,
whereas one thinks of quantitative values as being continuous. At the stage of causal modeling that this
experiment was drawn from, estimating the strength of influence between variables in causal models was
not yet technically feasible. The experiment presented here is the result of a compromise between what I
knew how to do and what I desired to accomplish.
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derive continuous values was devised by using the literature and EHR to identify a focal
set and using all unique combinations of that set as input to causal discovery algorithms.
By dividing the number of resulting causal edges detected by the number of
permutations, a metric with a continuous value was attained with which to calculate the
aggregate performance of the causal discovery algorithm using AUROC. AUROC
provides a means to weigh sensitivity (or recall: the ability to identify True Positives)
against specificity, the capacity of a classifier to guard against the identification of
spurious signals as positive. The evaluation metrics and procedure will be discussed in
greater detail below.
5.2 Materials and Methods
Data Sources. To evaluate this hypothesis, the same pre-processed EHR data and
reference dataset were used as in Chapter 4 (Ryan, Schuemie, et al., 2013; UTHealth
BIG., 2017).
Discovery Pattern for Confounding Variable Discovery. Semantic Vectors
provides an interface that permits searching PSI spaces for concepts that populate
particular predicate discovery patterns, which I used to identify the most strongly
associated confounding variable candidates for each drug/adverse event pair. I used the
following discovery pattern to identify possible confounding variable candidates: “drug
TREATS confounder; confounder CAUSES adverse_event.” For example, given
rosiglitazone and gastrointestinal bleeding, “diabetes mellitus, non-insulin-dependent”
was a result. This discovery pattern was chosen for its ability to identify co-morbidity
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type “true”/”proper” confounders39; that is, mutual causes that increase the co-occurrence
of both the explanatory and the outcome variables (Judea Pearl, 2009).
TETRAD and FGeS. TETRAD is an open source causal modeling and discovery
toolkit written in Java that has been in continuous development at Carnegie Mellon
University since the early 90s (Scheines et al., 1998). Depending on one’s choice of
algorithm, the input may be discrete, continuous, or mixed. The discrete version of the
Fast Greedy Equivalence Search (FGeS) included with TETRAD with default parameters
(Ogarrio et al., 2016) was used to infer graph structures from the EHR data.
FGeS recursively adds and then subtracts directed edges between nodes until the
Bayesian Information Criterion40 (BIC) is minimized. The output consists of a family of
score-equivalent graphs which encode plausible dependency relationships given these
data such that the orientation of the directed edges could not be determined from the data
alone, i.e., graphs encoded by this structure have the same BIC score (Heckerman et al.,
1995, 1995). However, background knowledge can be used to orient these edges, as
causal predicates have inherent directionality. The resulting graph structure of a
literature-derived confounding variable candidate should have a graph within this
equivalence class with directed edges to both the drug and the adverse event
(“confounder inclusion criterion”).

39

Proper confounder as per the Greenland et al. definition (S. Greenland et al., 1999; Weinberg, 1992).
For continuous Gaussian data: 𝐁𝐈𝐂 = 𝐧 𝐥𝐧(𝛔 𝟐̂𝐞 ) + 𝐤 𝐥𝐧 (𝐋 ̂) where 𝑳 ̂ = the argmax of the likelihood
function, x = data, n = number of observations in n, k = number of parameters {Citation}.
40
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Combinatory Expansion of Confounding Variable Candidates. If I have a set
of three confounding variable candidates, denoted {A, B, C}, this will result in seven
unique combinations of focal sets: A, B, C, AB, BC, AC, and ABC (AB and BA are
equivalents). At five confounding variable candidates per focal set, there are thirty-one
unique combinations. I evaluated these because it is not known which combination of
confounding variable candidates, if any, would cause spurious drug/adverse event graph
dependencies to vanish.
Analysis of Observational Clinical Data. The steps were as follows:
1. Confounding variable candidate identification. Query PSI vector space for
confounding variable candidates given each drug/adverse event pair for
confounding variable candidates and extracted EHR data.
2. Confounding variable candidate validation. Use TETRAD/FGeS to construct
and validate confounding variable candidates individually in ranked order of their
relatedness to the PSI query, by testing each individually for directed edges to the
drug/adverse event pair, and halting when five of the top-ranked confounding
variable candidates for each drug/adverse event pair had been validated.
3. Confounding variable candidate permutation. Use combinatorial expansion to
permute all combinations of confounders.
4. Causal discovery. For each of the confounding variable candidate permutations,
use TETRAD/FGeS to determine whether or not a causal edge from predictor
(drug) to outcome (adverse event) variable is present in the graph with minimal
BIC.
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5. Aggregation. Calculate the proportion of confounding variable candidate
permutations for which a causal edge is present, and evaluate aggregate
performance using AUROC from the ranked order drug/adverse event pairs per
this proportion (such that those pairs with the highest proportion of causal edges
across permutations will be most highly ranked).
Evaluation Procedure. To calculate and compare performance, I calculated the
Area Under the Curve of the Receiver Operating Characteristic curve (AUROC), which
is widely used to evaluate the performance of classifiers against a ground truth of positive
and negative controls, based on the ranked order of a continuous estimate of the strength
of predicated relationships. AUROC treats both Types I (“false negative”) and Type II
(“false positive”) errors symmetrically. For baseline scores, I used correlation coefficients
from logistic regression models without the incorporation of literature-derived
confounding variables.
Evaluation Metrics. Causal model scores are calculated from the number of
directed edges from the drug to the adverse event divided by the total number of
permutations. The hypothesis is that the proportion of directed edges of positive cases in
the reference dataset from the drug to their respective adverse events will be higher for
the group of positive control drug/adverse event pairs than for the negative pairs in the
reference dataset. In other words, the current study tests whether the associations from
co-occurrence in the clinical data of a drug/adverse event pair are diminished conditional
on sets of other concepts (i.e., validated confounding variable candidate permutations).
Figure 6 demonstrates how the scoring metric is applied:
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Figure 6. Illustration of Scoring Metric for Focal Set Permutations.

5.3 Results
Table 5
Results from Focal Set Permutation Experiment
Adverse events

Total

Baseline

Causal Models

24/64

0.5547

0.6598

81/37

0.4957

0.5449

35/64

0.4946

0.56

24/67

0.5643

0.6912

164/232

0.504

0.5813

AKI (Acute Kidney
Injury)

ALI (Acute Liver
Injury)

AMI (Acute
Myocardial Infarction)

GIB (Gastrointestinal
Bleeding)

Total

Note. This table presents the AUROCs as calculated from the aggregated logistic
regression coefficients (Baseline) and the fraction of directed edges from the causal
graphs. Pairs = number of test/control drug/adverse events from the Ryan reference
dataset. AUROCs in bold indicate that the causal models outperformed the baseline
models for that phenotype.
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5.4 Discussion
Analysis of Results. 1915 out of 2124 total tested confounding variable
candidates (for 399 drug/adverse event pairs each with five confounders) were both
present in the clinical notes and passed validation, so the confounding variable candidate
yield rate was 90%, indicating that LBD can identify confounders in clinical notes. As
shown in Table 5, the overall aggregate performance boost that approached ~ 0.08 over
statistical models confirms our hypothesis that the identification problem of confounding
can be partially resolved by using the literature to inform feature selection41 (an area that
I have addressed earlier with using LBD for statistical models) (Malec et al., 2016). The
method performed the best when the baseline AUROC for drug safety signal was
sufficiently above the level of noise (~ 0.5 AUROC). GIB, followed by AKI, had the best
baseline AUROC. By contrast, MI and ALI hardly budged from noise to signal,
indicating that the method requires a reliable initial baseline to be effective.
Practical Significance. Better detection methods in pharmacovigilance, if
implemented, hold promise for improving public health and safety. For example,
enhanced methods of drug/adverse event detection in observational clinical data could
facilitate the prioritization of drug/adverse event relationships for critical review. Given
the extent of the exposed population and the prevalence of adverse drug events, an
improvement of even a few percentage points could have a substantial impact.

41

Overall results were slightly higher (~ 0.08) when calculated using only pairs where drug occurrence ≥ 100 or 500.
0.75 is a desired level of significance desired typical for clinical applications.
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In Chapter 4, LBD methods were used for feature selection of confounders to
adjust for plausible confounding with the same set of clinical data. Both single predicate
(CAUSES and PREDISPOSES) and dual predicate (“drug TREATS x; x
COEXISTS_WITH adverse_event”) discovery patterns were deployed to identify
confounding variable candidates. With the single predicate discovery patterns, the
influence from the confounder was only exerted explicitly in the literature on the
outcome and can be thought of as an alternative etiology. Dual predicate discovery
patterns performed the best overall with a modest ~ 0.02 AUROC improvement over
unadjusted models. My analysis was that the dual predicate discovery patterns identify
confounding variable candidates that influence both predictor and outcome, fulfilling the
graphical criteria (Judea Pearl, 2009). In the Chapter 4, I used a different dual predicate
discovery pattern, and these results affirm previous observations about the utility of dual
predicate discovery patterns for identifying confounders with the bonus that causal
models with validated “true” confounders improved upon the performance of adjusted
dual predicate statistical models. I reduced the False Discovery Rate (FDR), where
𝐅𝐃𝐑 = 𝐓𝐫𝐮𝐞 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐓𝐫𝐮𝐞 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 + 𝐅𝐚𝐥𝐬𝐞 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 , from 0.5 to 0.38 with causal

models. Although the performance increase is substantive and better in general adjusted
standard statistical models (for purely EHR-based pharmacovigilance), it does not
approach the performance obtained in the work of Li et al. with extra-EHR data sources,
where adjusted EHR statistics with adjusted FAERS performance improved upon
adjusted FAERS and EHR performance alone (Y. Li, Ryan, Wei, & Friedman, 2015a).
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AUROCs improved across all adverse events with this chapter’s method in
contrast to the results from Chapter 4. In addition, the improvements were more
considerable overall – an 0.08 improvement in the aggregate. Starting with similar
baseline scores, Li was able to increase the AUROC considerably by integrating FAERS
data (Y. Li, 2015). This indicates that a future direction of research should be in
synthesizing data-driven confounding variable discovery methods with literature-derived
covariates to see how this affects performance. Note that the discovery pattern of “drug
TREATS confounder; confounder CAUSES adverse_event” only identifies
comorbidities, while the discovery pattern in Chapter 4 identifies both comorbidities and
co-medications.
Limitations of (and Lessons from) the Current Approach. One limitation is
that my search for confounders was relatively shallow, having commenced confounder
permutations after reaching five validated confounding variable candidates.
Computational demand scales with the number of confounders. Five validated
confounding variable candidates result in thirty-one permutations per drug/adverse event
pair. Increasing to ten confounding variable candidates would leave 1032 permutations which can take twelve hours to run on a Linux workstation with 64GB RAM and eight
Xeon CPUs. I chose five confounding variable candidates because I could collect results
for all drug/adverse event pairs for a single adverse event within a reasonable amount of
time (7-8 hours overnight). There may be some theoretical justification for using a
limited number of confounders as it is possible to “overcontrol” causal associations
(Elwert & Winship, 2014; S. Greenland et al., 1999). For instance, increasing the number
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of confounders to ten had the effect of reducing recall (recovering causal edges in the
cases/True Positives), while increasing specificity (decreasing the number of False
Positives).
An additional limitation arises from the available EHR data, which may not have
a sufficient number of drug/adverse event co-occurrences, as the performance from
analyses of FAERS data is usually better than results from any EHR data source (Y. Li et
al., 2015a).
One perplexing problem arose from three drug/adverse event pairs for myocardial
infarction for which the proposed method could not identify any confounders (these are
not included in Table 5). I suspect that confounders for myocardial infarction identified
by my method, e.g., hypertension, coronary arteriosclerosis, metabolic syndrome, could
have helped if incorporated into these models. Note that the discovery pattern limits
result sets of potential confounders to comorbidities, although co-medications (for
example, aspirin and acetaminophen for gastrointestinal bleeding and liver failure,
respectively) often make exemplary confounder candidates, so there remains the question
of the optimal mixture of confounder types. These factors (along with SemRep’s low
recall of ~ 0.64) may have impacted my system’s performance by missing potential
confounders (Kilicoglu, Fiszman, Rosemblat, Marimpietri, & Rindflesch, 2010).
Another consideration is that reference data sets, however essential to the scientific
enterprise, may not be entirely accurate, as knowledge about drugs and their side-effects
accumulates (Hauben, Aronson, & Ferner, 2016).
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The implicit assumption in the calculating of the score of each
drug/adverse event pair is that each permutation of the set of confounders is
equally valid. This simplifying assumption, while likely invalid, was nonetheless
useful as overall performance eclipsed that of the statistical models in Chapter
4. This could be addressed by using an information theoretic metric to
encapsulate data/model goodness of fit, e.g., Bayesian Information Criterion,
for each permutation of a confounder set, where each permutation could be
assigned a weight.
The next chapter counters with a more principled approach to causal
modeling, while building on the insights and essential lessons of what worked
for LBD predictive modeling: respectively, dual predicate discovery patterns to
identify focal sets of confounding variable candidates (Chapter 4) and the
exploitation of the directionality inherent in causal predicates (Chapter 5). The
experiment described in Chapter 6 infers the data generating process gleaned
from the EHR data, whereby such generative causal models can be used to
simulate the effects of interventions and to quantify average treatment effects.
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Chapter 6: Quantifying the Average Treatment Effect from a Mutilated DAG
… [T]o explain an historical event is to find the reasons for its occurrence, and to
do that is to re-enact the circumstances and states of mind of the actual agents
whose actions brought about the event in question. The historian gives ‘the’
reasons for that event when he gives ‘their’ reasons for it.
Dov Gabbay, 2006, pg. 94

In the experiments described by the previous two chapters, the struggle was to
first identify what species of intervening variable would be most helpful for the
task of amplifying pharmacovigilance signals in EHR data. Dual predicate
discovery patterns were found to be the most effective. These reasoning
pathways proved effective for identifying not only concepts that were associated
with both the predictor and outcome variables, but mutual causes of them both,
i.e., the operative definition of confounder. This chapter presents an experiment
to explore the frontiers of what such precisely defined confounders can do42.
A causal model by definition describes a data generating process43. In this
study, data generating processes are functional causal DAGs. As in the previous
chapter, expert knowledge derived from the literature is directly mapped as a
graph prior and instantiated with observational data derived from EHR. The
novel feature of the current experiment is that the causal DAG generate
simulated data from a mutilated posterior model with which to calculate
average treatment effects, or ATE.
42

Owing to their ability to answer counterfactual queries, Koller distinguishes the class of causal models
discussed in this chapter as being “functional causal models” in contrast to plain causal models (Koller et
al., 2009). In this chapter, techniques are described which can not merely describe conditional probability
distributions with causal assumptions, but answer counterfactual queries.
43
For more on data generating processes, see (Hendry & Doornik, 2014).
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The methods evaluated in this chapter are the state-of-the-art refinement of my
methodology and constitute a principled method for the incorporation of
literature-derived confounding variable candidates into causal models.
6.1 Introduction
This study addresses the weaknesses of the ad-hoc permutation-based procedure
described and evaluated in the previous chapter and documents the current stage of
evolution of the methods developed for this dissertation. Specifically, this study assesses
the ability of LBD-informed causal inference models to quantify the effect of the
explanatory variable (drug exposure) on an outcome of interest (an adverse event) using
observational clinical data derived from EHR. The identification of literature-derived
confounders can facilitate the process of de-confounding, (or "screening off" spurious
correlations from descriptive statistics) in observational data, by imposing constraints
from a priori domain knowledge on the topology of the causal graph. By incorporating
confounders into causal models, one can perform experiments/interventions with the
resulting data generating model (J. Pearl et al., 2016; Judea Pearl, 2009; T. J.
VanderWeele & Shpitser, 2013).
6.2 Technical Background
The following subsections provide an overview of the essential mathematical machinery
and concepts required estimating ATE. These core components can be summarized as
follows:
1.) Graph factorizations and conditional independence (section 6.2.1).
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2.) Counterfactual queries via graph mutilation (section 6.2.2).
3.) Mutilated graph simulations for ATE(𝐝𝐫𝐮𝐠 Þ 𝐚𝐝𝐯𝐞𝐫𝐬𝐞_𝐞𝐯𝐞𝐧𝐭) (section
6.2.3).
Since the graphical approach for representing causal relationships (wherein nodes
represent variables and directed edges represent causal relationships [or “dependencies”
between variables]) is the most intuitive to grasp, the next section starts with graphs 44.
6.2.1 Graph factorizations and conditional independence
A Bayesian network consists of a network structure as directed edges that encode intranode (variable) dependencies and a the conditional distribution of each nodes’
adjacencies. When observed values of variables represented are populated, the network is
said to be instantiated. If the joint density distribution inferred from these values are
reflected in the anticipated network structure, that structure is said to be compatible with
its instantiation (Darwiche, 2009; Koller et al., 2009).
Consider a data set A that consists of a set of random variables X and is described
by a directed acyclic graph G. The (causal) Bayesian network B = (G, X) and Q denote
the parameters of the global distribution of X, such that Q is i.i.d. with X, so that B = (G,
Q) (and Q can denote the sufficient statistics of appropriate marginal and joint

distributions given A, e.g., Bernoulli/binomial/multinomial. if discrete, Gaussian/Poisson.
if continuous, and so on) (Darwiche, 2009). The structure and parameter learning process

44

Beyond being merely easy for humans to interpret, graphs have convenient mathematical properties that
are useful for summarizing dependency relationships a set of random variables. In short, dependency
relationships may be easily translated into either graphical or factorization form. These properties are
summarized in great detail elsewhere (Koller et al., 2009; J. Pearl, 2014).
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(noted above) is decomposable into the following factors (Koller et al., 2009; J. Pearl,
2014; M. Scutari & Denis, 2014; Marco Scutari, 2009) [Equation 1]:
𝑷 𝑩 𝑨 = 𝑷 𝑮, Q 𝑨 = 𝑷 𝑮 𝑨 𝑷 Q 𝑮, 𝑨 .
P(G|A), the first factor on the right side of Equation 1, denotes the structure (topology)
of the graph and can be further decomposed as follows [Equation 2]:
𝑷 𝑮 𝑨 = 𝑷 𝑮 𝒂𝒓𝒈𝒎𝒂𝒙 ∫ 𝑷 𝑨 𝑮, Q 𝑷 Q 𝑮 𝒅Q

45

P(G) represents the “subgraph”46 of the Bayesian network derived from domain (expert)
knowledge as a structural (graph) prior. G encodes conditional probabilities of the
random variables in X from data A parameterized by Q.

Figure 7. Illustration of a “true confounder” with a set of random variables {x, y, z}.

45

Translated into plain English, this expression says: “find the values of parameter Q that maximize the
area under the curve (are the most likely) for graph G dataset A.”
46
The graph “subgraph” refers to how there may be unanticipated dependencies given the actual input data
that were not recalled in the literature. In LBD research, this refers to the subset of dependencies identified
in the literature (Cameron et al., 2013, 2015).
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6.2.2 Counterfactual queries via graph mutilation.
Given a set of random variables {x, y, z}, where z is a confounder that influences both x
and y, assume that we do not know the relationship between x and y. From a priori
knowledge (or experience47) we know that the value of z determines x and y. Variable z
is said to be their common “parent,” while x and y are z’s “children.” Since x and y have
a parent in common (“a mutual cause”), their values are statistically correlated. A
directed (“causal”) edge is drawn from x to y to represent the relationship about which
we wish to know more. The task is to determine the likelihood of x to influence or
determine the value of y, even in the presence of mutual cause z that influences them
both as depicted in Figure 8 below. Graph G is depicted below and the relationships
between its variables encodes their dependencies (G’ will be explained later).

47

In the case of this dissertation: the source of a priori knowledge is the literature.
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Figure 8. Illustration of graph mutilation/manipulation. To make the connection clear, in
calculating the Average Treatment Effect, one is “severing” the relationship between z
and x, cutting off the “back-door path”.

G factorizes as the following joint probability distribution [Equation 3]:
𝑷 𝒙, 𝒚, 𝒛 = 𝑷 𝒛 𝑷 𝒙 𝒛 𝑷 𝒚 𝒙, 𝒛
Since the task is to eliminate the noise emitted by the effect of z on x [Equation 4]:
𝑷(𝒙, 𝒚, 𝒛) 𝑷(𝒙|𝒛) = 𝑷 𝒛 𝑷 𝒚 𝒙, 𝒛
Note that the factorization of graph G’ is represented in the factorization on the righthand side of Equation 4. Given the dependencies depicted in the graph and its respective
factorization properties, a question one might ask is: how might we estimate the
magnitude of the relationship between x and y? To do this, the value of x can be fixed
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such that it is no longer susceptible to influence from z. This “fixing” or “setting
constant” the values of the explanatory variable x is the essence of the “do(.)” operator
introduced below.
To determine the direct effect of x on y, one can mutilate48 the graph by setting
(randomizing) the values of x (to 1 and then to 0), such that the post-intervention
distribution to reflect G’ above can be denoted by the following truncated factorization49
(P(x|z) is dropped as x becomes parentless [independent of z] due to randomization)
[Equation 5]:
𝑷 𝒛, 𝒚 𝒅𝒐 𝒙

= 𝑷 𝒎𝒖𝒕𝒊𝒍𝒂𝒕𝒆𝒅 (𝒛) 𝑷 𝒎𝒖𝒕𝒊𝒍𝒂𝒕𝒆𝒅 𝒚 𝒙, 𝒛

= 𝑷 𝒛 𝑷(𝒚|𝒙, 𝒛)

By dividing Equation 3 by P(x|z) as per Equation 4 and combining it with Equation 5, I
obtain a telling pre- and post-intervention ratio [Equation 6]:
𝑷 𝒛, 𝒚 𝒅𝒐 𝒙

= 𝑷(𝒙, 𝒚, 𝒛) 𝑷(𝒙|𝒛)

We can perform adjustment by marginalizing over z (J. Pearl et al., 2016) [Equation 7]:
𝑷 𝒛, 𝒚 𝒅𝒐 𝒙

= 𝒛

𝑷 𝒛 𝑷(𝒚|𝒙, 𝒛)

Counterfactual and Potential Outcomes Framework. Confirming our intuition,
the P(x|z) is critical for estimating the effect of do(x). To nullify the dependency between
the confounder and the explanatory variable, the explanatory variable x can be set to a
value of 1 and then to 0, where 1 indicates presence (or treatment/case) and 0 denotes
absence (or placebo/control) (K. Lee, Small, & Rosenbaum, 2018; J. Pearl et al., 2016;
Rosenbaum & Rubin, Donald, 1983; M. Scutari & Denis, 2014) [Equation 8]:

48
49

Elsewhere, this is referred to as “graph surgery” (S. Greenland et al., 1999; Judea Pearl, 2009).
The factorization is referred to as being “truncated” because the P(x|z) has been removed.
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𝑷 𝒚 𝒅𝒐 𝒙

= 𝑬 𝒚 𝒙 = 𝟏 − 𝑬(𝒚|𝒙 = 𝟎)

Equation 8 is a means to express the severed dependency of P(x|z) in G’. When
the graph is modified to remove the influence of z on x, a more accurate picture of the
relationship between x and y emerges. This intuition that underlies the notion of the
“back-door” criterion is that the graph is to permit the estimation of the causal influence
of x on y irrespective of the influence of z on x (the “back-door path”). The apparent
effect of x on y may or may not be spurious, and this procedure facilitates this estimation.
The “back-door criterion” is discussed at length elsewhere (Morgan & Winship, 2015;
Judea Pearl, 2009; T. J. VanderWeele & Shpitser, 2013).
Note the operations just described are “counterfactual” in that we are not using
the joint distribution from the data, but estimating the relationships from a manipulated
distribution. Recall that the relationship between z and x (nullifying the “back-door”) is
severed and the values of x are fixed to 1 and 0, so as to measure an average effect of y
on x. P(y | do(x)), referred to as “average causal estimate” or “average treatment
estimate”, or ATE, is not the same as P(y|x) (association). However, they could be the
same, in an hypothetical case, if the x and y are not confounded50.
6.2.3 Mutilated graph simulations for ATE(𝒅𝒓𝒖𝒈 Þ 𝒂𝒅𝒗𝒆𝒓𝒔𝒆_𝒆𝒗𝒆𝒏𝒕)

50

Note also that we cannot determine how an individual patient “p” would fare given a treatment since at
one time slice patient p’s outcome Y can only hold discrete values, 1 or 0, not both. This is why the
expectation or mean is calculated (the average treatment effect). In performing the ATE calculation, there is
an explicit assumption that the patient has two values simultaneously. This is why the potential outcomes
framework methods is referred to as being “counterfactual.”
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In probabilistic graphical models, the most common way to estimate the set of
parameters Q is to perform a maximum likelihood estimate. This finds the best set of
edges given input data (and assumptions from domain knowledge about the orientation of
the edges).
However, for causal models, one does not stop at an estimate from the joint
density distribution but uses that distribution as the means to generate data from a
perturbed or “mutilated” distribution. In this mutilated distribution, the predictor
variable’s values are fixed as per Equation 8 above (to remove dependency to a common
cause [the P(x|z) term in the graph factorization]).
A causal model specifies both qualitative (the edges/arcs between nodes/vertices
in the graph) and quantitative relationships. The latter is embodied in another stream of
influence on causal inference deriving from econometrics, more specifically of structural
equations modeling (SEM) (Bollen, 2014; Bollen & Long, 1993; Goldberger & Duncan,
1973; J, 2008; Judea Pearl, 2009).
An example will illustrate a simple (causal) SEM as a data generating process
(Hendry & Doornik, 2014). Take variables {x, y, z} and presume that their respective
relationships and parameters Q have been learned from a set of observational data. Let us
presume that these variables are related to each other as per Figure 7 (from earlier in this
chapter) and we define z as a discrete binary, such that:
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𝐳 ~ 𝐁𝐢𝐧𝐨𝐦𝐢𝐚𝐥 𝟏𝟎𝟎𝟎, 𝟎. 𝟐
𝐱 ~ 𝐟(𝐳)
𝐲 ~ 𝐟(𝐳, 𝐱)
From these equations, we can see that z is exogenous, while x is dependent on the value
of z and y is dependent on the values of both x and z. With this data generating model,
the average effect of x on y may be estimated by shutting off the relationship between x
and z by setting the value of x value to 1 and subsequently to 0 (severing the “back-door”
path, i.e., the P(x|z) term in the graph factorization).
The results of this operation are a new “mutilated” set of equations that now look
like this:
𝐳 ~ 𝐁𝐢𝐧𝐨𝐦𝐢𝐚𝐥 𝟏𝟎𝟎𝟎, 𝟎. 𝟐
𝐱 ~ {𝟏, 𝟎}
𝐲 ~ 𝐟(𝐳, 𝐱)
To calculate the average treatment effect, or ATE, one is calculating an expectation or
mean. This mean is not the mean of the observed, original joint density, but those of the
mutilated models. Using these mutilated models (data generating processes) to simulate
data, a conditional probability query can be performed with x = 1 and x = 0 on data
generated from the new mutilated distributions, then one simply subtracts the results
[Equation 9], where E is the expectation or mean51:

51

k

𝐸 = l ∑lpqk(𝑦 | 𝑥p )
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𝑨𝑻𝑬(𝐱 Þ 𝐲) = 𝑬 𝒚

𝒅𝒐(𝒙 = 𝟏)) − 𝑬(𝒚 | 𝒅𝒐 𝒙 = 𝟎 )
= 𝟏 𝒏 𝒊=𝟏 𝒏 𝒚

𝟏 𝒏 𝒚

𝒙 = 𝟏) −

𝟏 𝒏 𝒊=

𝒙 = 𝟎)

To summarize: to compute the ATE, a mean is calculated from simulated data drawn
from the joint density distribution of the two mutilated causal Bayesian network (where x
is set to 1 and subsequently to 0)52. In graphical terms, it severs the backdoor path (flow
of information from the confounder to the predictor. To define ATE in coarse terms, the
ATE is the mean “delta” (change) that one could expect of an adverse event occurring
from each increase drug exposure in that population; it is sometimes referred to as the
stable unit treatment value assumption53, or SUTVA (Cox, 1958).
In machine learning, sequential (data generating) processes such as those described above
may be simulated using what is variously referred to as “particle filtering” or “logic
sampling” methods (Darroch, Lauritzen, & Speed, 1980; Fung & Chang, 1990; M.
Henrion, 1987; Max Henrion, 1988; Koller et al., 2009; M. Scutari & Denis, 2014). In
logic sampling, one has a set of variables that are defined as parameterized distribution
functions. To simulate data, the process runs forward. Depending on the implementation,
there is a “burn-in” period of iterations to allow for the sampling to attain the intravariable parametric targets (Darwiche, 2009; Koller et al., 2009; M. Scutari & Denis,

52

The broad strokes of this method were first devised by Polish agronomist Jerzy Neyman who desired to
answer “what if?” or “counterfactual” questions about which seeds to plant given what is known about their
crop yields (Neyman, 1937; Rubin, 1990).
53
Since the data are so coarse-grained, this is not to be taken at face value, but only in relative terms.
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2014). For mutilated graphs an updated rendition of logic sampling is used called
“likelihood weighting” (M. Scutari & Denis, 2014; Shwe & Cooper, 2013).
Recap: synthesizing the pieces. The steps for simulating data to perform such an
estimate from EHR data are as follows:
1. Learn the graph structure with oriented edges between variables for each
drug/adverse event pair in the OMOP reference dataset (Ryan, Schuemie, et al.,
2013).
2. Given the data, learn the parameters Q that define the intra-variable relationships.
3. Generate data using the mutilated versions of the causal models, fixing
explanatory/drug exposure variable (“evidence”) to 1 and 0, and performing
conditional probability queries on the simulated data.
4. Calculate the ATE from the mutilated model.
5. Aggregate the results to calculate AUROC from rank ordered ATEs for the
OMOP reference data set.
Steps 1 and 2 of the procedure are described in section 6.2.1 and Steps 3 and 4 are
described in sections 6.2.2 and 6.2.3.
6.2 Materials and Methods
6.2.1 Data and Knowledge Resources.
EHR data. To evaluate this hypothesis, the same pre-processed EHR data and
reference dataset were used as in Chapter 4 and Chapter 5 (Ryan, Schuemie, et al., 2013;
UTHealth BIG., 2017).
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Discovery Pattern for Confounding Variable Discovery. Semantic Vectors
provides an interface that permits searching PSI spaces for concepts that populate
particular predicate discovery patterns, which I used to identify the most strongly
associated confounding variable candidates for each drug/adverse event pair. I used the
following discovery pattern to identify possible confounding variable candidates: “drug
TREATS confounder; confounder CAUSES adverse_event” (the same discovery
pattern as in Chapter 5). This discovery pattern was chosen for its ability to identify
mutual causes of both the explanatory and outcome variables in Chapter 5.
6.2.2 Methods
What follows in this section is a brief breakdown/overview. This is followed up with
more details about each step of the procedure.
Core steps to evaluate ATE. The core steps of the method to quantify ATE are as
follows:
1. Query PSI vector space for confounders in ranked order of relevance.
2. Test each confounding variable candidate for directed edges to both the drug
and the adverse event using the clinical data, stopping after obtaining ten54 valid
confounding variable candidates for each drug/adverse event pair.

54

I tested many variations of covariate threshold. In most cases, the more covariates identified, the better
the models performed.
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3. Build predictive (statistical [multivariate logistic regression] and causal)
models for each drug/adverse event pair incorporating the validated LBD-derived
confounders.
4. Calculate the ATE using mutilated simulation data generated from the
causal models for each drug/adverse event pair.
5. Calculate AUROCs from rank ordered scores (baseline regression coefficient,
adjusted regression coefficient, ATE) for the drug/adverse event pairs in the
reference dataset.
The next subsections will break the novel procedures above into manageable parts.

6.2.2.1 Testing Confounding Variable Candidates.
There are two critical tasks after identifying confounding variable candidates concepts:
1.) Determine if confounding variable candidate appears in the data (if not,
move to the next confounding variable candidate).
2.) Determine if the confounding variable candidate fulfills the graphical
criteria as a confounder.
If the confounding variable candidate is not in the clinical data, it cannot be instantiated.
However, if there are data for the identified concept, then it is tested. Simply stated, in
order for a confounding variable candidate to be retained for the purposes of building the
causal model, i.e., becomes part of the “causal story”/”focal set”, it must first be
instantiated with EHR data along with the drug and adverse event. If there is there is a
subgraph in the resulting partial ancestral graph (PAG) that fulfills the pattern of: drug
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Ü confounder Þ adverse event, then the confounding variable candidate is retained for

the next step (building the model).
To construct the causal models for testing confounding variable candidates, the
hill climbing algorithm in the bnlearn55 R package (M. Scutari & Denis, 2014; Marco
Scutari, 2009). The hill climbing algorithm recursively adds and subtracts directed edges
until the Bayesian Information Criterion is minimized. Note that the purpose in the
current experiment is not so much to learn structure, but to assume that there is a
relationship between the putative predictor/cause (drug exposure) and outcome (the
adverse event). The mutual causes or literature-derived confounders are used to screen
off the relationship between the drug and the adverse event.
The output consists of a family of score-equivalent graphs which encode plausible
dependency relationships given these data such that the orientation of the directed edges
could not be determined from the data alone, i.e., graphs encoded by this structure have
the same BIC score (Heckerman et al., 1995, 1995). However, background knowledge
can be used to orient these edges, as causal predicates have inherent directionality. The
resulting graph structure that results from incorporating literature-derived confounding
variable candidates have a graph within this equivalence class with directed edges to both
the drug and adverse event (“confounder inclusion criterion”).

55

The primary attractiveness of the bnlearn package stems not from its Bayesian structure learning
prowess, but its capacity to do most of the “functional” causal modeling toolbox sufficiently well and to
run in batch processes from the command line. For a formal comparison of causal Bayesian structure
learning packages available to the public see Ramsey et al. (J. D. Ramsey & Andrews, 2017).

97

6.2.2.2 Building causal models
Once the threshold for the number of confounding variable candidates has been reached
(the number of covariates) for inclusion in the focal set, the next step is to use these
concepts to populate a causal DAG/model. The causal DAG is instantiated with the
variable values in the EHR data. In this step, EHR data and an initial skeleton of a graph
(using the edge/arc orientations from the literature) is constructed.
To construct the LBD-informed causal models, the hill climbing algorithm in the
bnlearn R package (M. Scutari & Denis, 2014; Marco Scutari, 2009) is used, as per the
previous step, is used to learn the rest of the (inter-confounder) relationships and to fit a
model using maximum likelihood estimate (MLE). MLE attempts to identify an optimal
set of parameters given the graph structure and the observed data. These parameters may
then be used to generate simulated data (as per section 6.2.3).
The nodes of confounding variable candidates tend to be (but are not always)
highly correlated, so there is lots of “cross-talk” between the confounders. An example
graph generated from EHR data is provided below in Figure 9:
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Figure 9. Illustration of a causal graph instantiated with EHR data. Drug = methotrexate,
adverse event = acute liver failure (“ALI”). From the OMOP reference dataset (Ryan,
Schuemie, et al., 2013), positive control. For clarity, the number of confounders has been
reduced.
The graph provides an intuitive picture of some of the causal interactions between these
variables. For example, it is clear from the graph that methotrexate is prescribed as a
treatment for (therefore, observing it is CAUSED BY) psoriasis, ulcerative colitis, and
rheumatoid arthritis: but not for hypercholesterolemia. Others are more difficult to
interpret. For example, while one might anticipate raised cholesterol in advanced liver
disease, hypercholesterolemia is not commonly considered as a possible cause for liver
failure. Nonetheless, the ability to interrogate a visual representation of the relationships
inferred by the model can be informative in interpreting the assertions of causality that
emerge from it.
99

6.2.2.3 Calculate the ATE using mutilated simulation data
As mentioned earlier, a causal model not only describes a data generating process
(that which has been learned from observational or experimental data or both), but a
model that may be perturbed/mutilated/manipulated to see how the variables behave
under duress. The next sub-subsections describe how to implement these simulations
(Judea Pearl, 2009).
Simulating the data. Once a graph and its parameters have been learned from the
data, the next step is to manipulate this model.
In a standard conditional probability query (CPQ), the CPQ generates data using
the parameters of model, i.e., the joint density distribution learned from the observations.
The values of the variables of interest and an “n” for the number of simulations may be
applied as per the investigator’s interest.
The R package bnlearn provides the means to perform mutilated conditional
probability queries. In a mutilated CPQ, the investigator sets the “evidence”, e.g., drug =
{1, 0}, and specify an “event”, e.g., adverse event = 1. By setting the evidence for drug to
1 and then to 0, specifying the event to adverse event = 1, and running the query, and
subtracting the two results (as per Equation 8 and Equation 9), bnlearn‘s mutilated
CPQ function can calculate an ATE for each drug/adverse event pair from the EHR data
using weighted logic sampling simulation (Fung & Chang, 1990; Koller et al., 2009; M.
Scutari & Denis, 2014). For the results below, 10 9 simulated EHR record instances
were generated from causal models derived from EHR data. The simulations were
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implemented with the weighted logic sampling option in the bnlearn R package (M.
Scutari & Denis, 2014; Marco Scutari, 2009).
Evaluation Procedure. Coefficients from logistic regression were used to
calculate baseline scores. ATE was estimated by performing a conditional probability
query on mutilated graphs for each drug/adverse event causal model, as per Equation 8.
To evaluate performance, Area Under the Receiver Operating Characteristic curve
(AUROC) was calculated based on the ranked order of the ATEs.
6.3 Results
Parameter estimates from causal models improved performance over logistic regression
for three of four adverse events. Causal models improved upon unadjusted statistical
models by 0.0795 AUROC.
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Table 6
Results from Average Treatment Effect (ATE)
Adverse events

Total

Unadjusted

Adjusted

Causal Models

AKI (Acute Kidney Injury)

22/62

0.5672

0.5242

0.6957

ALI (Acute Liver Injury)

77/34

0.4798

0.5092

0.594

35/63

0.556

0.5424

0.5456

24/64

0.5417

0.5651

0.5866

158/223

0.4782

0.5054

0.5849

AMI (Acute Myocardial
Infarction)

GIB (Gastrointestinal Bleeding)
Overall

Note. This table presents the AUROCs as calculated from the aggregated correlation
coefficients from logistic regression (unadjusted and adjusted) and ATEs from the causal
models. Pairs = number of test/control drug/adverse events from the OMOP reference
dataset (Ryan, Schuemie, et al., 2013). AUROCs in bold indicate that the causal models
outperformed the baseline models for that phenotype.
6.4 Discussion
Causal models. There were improvements with causal models in all four adverse
events. The overall improvement was consistent and not significantly better than the
results from the chapter previous. The improvements for GIB and AKI over their
respective baselines were more modest for the causal models than for some of the
regression models in Chapter 4. An unexpected and notable improvement came from
ALI. Such an improvement for ALI has been absent in the results from the experiments in
previous chapters.
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The experiment in this chapter focuses on creating what Koller calls functional
causal models (Koller et al., 2009). In a functional causal model, one does not stop with a
picture or a joint density distribution, but takes these two (the graph and the distribution)
as a data generating process for further exploration and as a means to explore
hypothetical questions and scenarios that may not be present in the original/observed
data. That is, the experiments in this chapter are not only data-driven, but model-driven.
The nature of the improvement in this chapter is more conceptual than in the actualized
improvement of performance. That is, the advance described allows for more complex
models that will be addressed in the next chapter.
Logistic regression models. The adjusted logistic regression scores have been
included to see how useful this discovery pattern is for logistic regression. The
improvements overall were slight compared with causal models and did not fair well in
comparison with the dual predicate discovery pattern “drug TREATS x; x
COEXISTS_WITH adverse_event” applied to the EHR data in Chapter 4. This may be
because the “drug TREATS confounder; confounder CAUSES adverse_event”
discovery pattern identifies only comorbidities, while “drug TREATS x; x
COEXISTS_WITH adverse_event” can also identify co-medication-type confounding
variable candidates. This indicates that discovery patterns besides “drug TREATS
confounder; confounder CAUSES adverse_event” should be explored to supplement comorbidity-type confounders identified by that discovery pattern in future work in LBDinformed predictive modeling.
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Li reported notable improvements using data-driven confounding discovery
methods (Y. Li, Ryan, Wei, & Friedman, 2015b). Inasmuch as natural language
processing (NLP) facilitates research in the text mining of EHR, NLP can also be a
limiting factor. Confounders that are present and have been “measured” in the EHR may
be absent on the literature side; conversely, not all useful confounders may have been
identified in the literature. In light of this, logical follow-up would be to integrate datadriven confounding discovery methods with the current literature-based approach.
For the sake of comparison, the AUROCs of several EHR-based Pharmacovigilance
methods has been included below in Table 7. Note that the performance patterns are not
strictly comparable owing to different sample sizes and populations, but have been
included here for convenience and to provide context. Note the similar starting points for
both Li et al. (Y. Li, 2015; Y. Li et al., 2014) and UTH. The causal graphs improve upon
the performance of the regression-based models, but fare poorly in comparison with
meta-analysis. However, should the causal models be the starting point, meta-analysis
should exceed the current state of the art of EHR-based pharmacovigilance barring nonlinear effects.
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Table 7
Performance Summary of EHR-based Pharmacovigilance Methods
AEs

UTH
baseline

Overall 0.50

Li et al.
baseline

Li et al.
lasso

0.53

0.51

UTH
Adjusted
Stat Model
0.51

Causal
Models
Graphs
0.58

Causal
Models
ATE
0.58

Li et al.
MetaAnalysis
0.73

Note. This table presents the AUROCs as calculated from the aggregated correlation
coefficients from logistic regression (unadjusted and adjusted) and scores from the causal
models from the OMOP reference dataset (Ryan, Schuemie, et al., 2013).
Models of 391 of the 399 drug/adverse event pairs in the OMOP reference dataset
(Ryan, Schuemie, et al., 2013) were constructed. In some cases, confounding variable
candidates were absent (as was the case for three drug/adverse event pairs for MI in the
previous chapter). Having set the threshold to ten, the models of five drug/adverse event
pairs were not able to constructed as the number of validated confounders did not reach
the threshold.
This chapter has evaluated a method to calculate the Average Treatment Effect56,
or ATE, using EHR data. Calculating ATE is but one step toward harnessing the richness
of EHR data for pharmacovigilance. The steps beyond ATE will be discussed in the next
and final chapter.
Work on the methods described began with a vague idea that intervening
variables having mechanistic causal relationships could be critical for

56

The fundamental problem of causal inference is that causes cannot be directly observed (but they may
be inferred from the average value of the response between exposed and unexposed population), as per
Holland (Holland, 1986).
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predictive modeling. The research has progressed from an amorphous,
exploratory conception of “in-between” variables to an increasingly refined
definition of confounding. The limitations, contributions, and directions of
future work of the research program will be presented in the next chapter in
detail.
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Chapter 7: Summary, Contributions, and Limitations
In this, the concluding chapter of my dissertation, I will summarize my research,
underscore its scientific contributions and limitations, and provide some ideas on how I
plan to overcome those limitations in future work.
Innovations of Present Work. The first noteworthy accomplishment of this work
is the development of a generalizable method through which knowledge extracted from
the literature can be used to identify confounding variables for statistical and causal
modeling. Confounding variable discovery was achieved by adapting methods from
literature-based discovery (LBD) and specifically the use of “discovery patterns”
(patterns of predicates that may indicate relationships of a particular type) to this novel
task domain. A key finding from this novel component of the project is that when the vast
majority of variables identified in this manner do, in fact, represent “true confounders,”
or mutual causes of both predictor and outcome variables (Judea Pearl, 2009).
In Chapter 4, I demonstrated that literature-derived confounders could be included
in statistical (logistic regression) models to improve signal detection using a publicly
available reference dataset.
In Chapter 5, I showed that literature-derived confounders could be incorporated
into causal models and using the graph structure of the resulting models alone, there was
a 7-8% improvement in signal detection over unadjusted baseline.
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In Chapter 6, I presented a method to estimate average treatment effect, or ATE, of a drug
to cause an adverse event given observational data derived from EHR and causal models
informed by literature-derived confounders. The ATE was estimated by:
1.) learning the topology of the observational data given literature-derived
confounders and accompanying subgraph structures inferred from semantic
constraints;
2.) estimating model parameters (the joint distribution function) of the causal
model that has been learned from the clinical data; and
3.) performing a conditional probability query on a “mutilated” version of the
graph by fixing the confounder to drug/explanatory edges to 1 and 0 and
subtracting these results.
Calculating the ATE had the effect of modestly improving performance over the purely
“qualitative” approach to causal inference taken in Chapter 5. However modest the
improvement, the success of such a principled approach using “functional causal models”
applied to even cross-sectional data opens many doors for methodological refinement and
future avenues of research.
7.1

Contributions
The contributions of this thesis to the discourse of biomedical informatics,

pharmacovigilance, and causal inference are as follows:
1. Novel domain of application of LBD methods. Previous work in LBD
has focused on generating novel therapeutic hypotheses, although recent
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work has been done in the area of detecting drug/adverse event signals in
the literature (Bruza & Weeber, 2008; Hristovski et al., 2006; Mower et
al., 2016; Shang et al., 2014; Smalheiser, 2012). The application of these
methods in general, and of distributed representations (PSI
representations) of discovery patterns in particular, to the problem of
identifying confounding variables for statistical and causal modeling is, to
the best of my knowledge, entirely without precedent. The present work
has demonstrated how causal knowledge embedded in the literature can
map onto observational clinical data to inform causal models. This
approach has the potential to eliminate a major bottleneck in the statistical
and causal modeling of observational data – the need for domain experts
to manually delineate a “causal story” describing variables of interest for
each hypothesis to be evaluated (J. Pearl et al., 2016). This finding has
broader implications for the science of informatics, as it shows that
confounders identified through literature-based discovery are of practical
utility in improving the accuracy of predictions made from such data.
2. I show that LBD methods can indeed be used to identify confounding
variables and that incorporating these automatically identified
variables improved the accuracy of predictive models (both classical
statistical and contemporary causal discovery methods). The studies
that I have presented have shown how if there is sufficient interaction
between the cue terms of interest, the variables derived from the literature
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suggestive of having the desirable property of being “confounders,” or
mutual causes of both the predictor and outcome variables, are useful for
reducing confounding observational clinical data.
3. The methods proposed may be generalized to other areas of
biomedicine. For example, these methods may be adapted to identify
control groups for RCTs (Fokkema et al., 2017). Specifically, a promising
area in which my approach to identifying confounders may be of value is
in the area of identifying subgroups for stratification in Phase III clinical
trials. That is to say that LBD-based identification of confounding
subgroups/demographic cohorts could be used to augment the scientific
scope or imagination of human experts and help to address unanticipated
deficiencies in clinical trials, given for example their being carriers of
specific alleles or having particular family medical histories. Some cohorts
of the populate could be more informative or representative for the task of
assessing safety and efficacy of pharmaceutical profiles before approval
and release to market.
4. Regarding a theoretical contribution, this dissertation demonstrates
how domain knowledge may be used as a means to constrain
hypothesis space so as to devise an explanation of empirical
observational data. The automatic generation of hypotheses using
domain knowledge is tantamount to implementing what is referred to as
tractable defeasible logic in silico (Gabbay & Woods, 2005). When one
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considers the cognitive constraints of the human mind, limits of time and
memory, it is remarkable what we as a species have been able to
accomplish. There are some tasks where humans excel, yet it has been
challenging to develop machines that can perform tractable abduction by
arriving at a plausible if not an ideal explanation of what has been
observed (what Herbert Simon refers to as “satisficing”) (SIMON, 1956;
Herbert A. Simon, 1955). It may be the cognitive limitations of human
memory forces us to concentrate on a causally relevant subset of features
(Cheng & Novick, 1990; Danks, 2014; C. N. Glymour, 2001; Holyoak &
Cheng, 2011). To accomplish such a task requires knowledge of context
and a database of causal knowledge that describes how the universe is
organized. In the approach to causal modeling that I have described, the
models apply semantic constraints given cue terms and process input EHR
data to infer the causal structure, magnitude of relationship between those
entities (the interpretation of the “parameter estimate”), and suggestions of
alternate etiologies or explanations of that input data (H.A. Simon, 2012).
Specifically, the contribution of this dissertation is to introduce practical
constraints on the scope of variables upon which causal modeling is
performed. The modeling of human cognition demands that we place
constraints similar to those that human reasoners do. While we have a
strong will to know and to learn, we also operate within constraints that
are imposed by limited resources of time and energy. As is the case with
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human reasoners, constraining causal reasoning in this manner offers
significant computational advantages and paves a path to large-scale
automated causal modeling.
5. The present work demonstrates the utility of causal methods within a
core area of biomedicine. To the best of my knowledge, except for some
research in the application of instrumental variables, the present work is
the first attempt to introduce fully automated causal modeling methods
within EHR-based pharmacovigilance.
6. This work demonstrates the utility of functional causal models that
can answer “what if” queries in biomedicine. Causal models make
assumptions explicit about a domain of knowledge if the form of directed
acyclic graphs and the functional forms that define the nodes subsumed in
them. Functional causal models instantiated with mixtures of
observational and experimental data allow for scientists to be able to test
the effects of hypothetical interventions and the falsifiability of their
causal assumptions in silico.

7.2

Limitations
One limitation of the present study was that the representation of the input data

was cross-sectional. In cross-sectional data, the primary unit of analysis is the individual
EHR record. This coarse-grained, but simple data representation lacks the means to
represent temporal constraints and patient-specific exposures. A study design that
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incorporates patient-level longitudinal EHR data may address this limitation in future
work (D, S, & K, 2008; Hoover & Demiralp, 2003; Moneta & Spirtes, 2006). An
additional limitation arises from the available EHR data which may not have a sufficient
number of cases (drug/adverse event co-occurrences), resulting in the poor performance
of the baseline models, apparently a common experience (Y. Li, 2015; Y. Li et al.,
2015b). As adequate performance without confounding adjustment appears to be a
prerequisite to substantive improvement once confounders were accounted for, this limits
the scope of application of my methods. This relatively poor performance with EHR data
alone is not unique to the current work – performance from analyses of FAERS data is
usually better than results from any EHR data source (Y. Li et al., 2015a). Another
consideration is that reference data sets, however essential to the scientific enterprise,
may not be entirely accurate, as knowledge about drugs and their side-effects
accumulates – recent work has identified specific deficiencies in the reference set that I
have utilized (Hauben et al., 2016). Current performance is not yet adequate to support a
practically useful pharmacovigilance system and falls short of the performance obtained
using other data sources, i.e., meta-analysis. It is not clear that this is only due to
inadequate numbers of cases and resultant lack of statistical power: there may be other
limitations of EHR data that come into play here. I believe that this limitation is due to
the generally poor baseline performance, which:
1.) constrains the potential of confounding adjustment,
2.) is typical with EHR-only analyses, and
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3.) has been addressed elsewhere successfully by combining EHR and FAERS
data, which is likely to be a fruitful area for future research.
7.3

Future Work
In my future work, I will aim to utilize patient-level longitudinal representations

of EHR data to address the limitations of cross-sectional causal.
Another idea to explore would the use of FAERS and EHR data together and the
exploration of causal modeling using longitudinal patient-level data with structural vector
autoregression (where patients become their own controls). I will also develop heuristics
to allow for more in-depth confounder search, and explore the potential application of
LBD methods to identify instrumental variables.
In any source of observational data, there is always likely to be confounding.
Greedy Fast Causal Inference (GFCI), which first runs FGES and then prunes edges with
a constraint-based structure learning algorithm, is an algorithm which can identify hidden
latent confounding (Ogarrio et al., 2016; J. D. Ramsey & Malinsky, 2016; TETRAD,
2017). GFCI, in other words, could direct the LBD mechanism in automated causal
inference to conduct a recursive search for confounding variable candidates until no
further latent confounding is discovered (or up to a pre-determined threshold or search
depth).
One challenge of integrating heterogeneous data is that it is likely that there is
missing data. However, these missing data could be imputed and become useful if the
pattern of missing data is not random, but systematic.
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Finally, I have implemented a method to calculate the Average Treatment Effect,
or ATE, using EHR data. Calculating ATE is but one step toward harnessing the richness
of EHR data for pharmacovigilance. Two promising directions for building on the
methods described (culminating) in Chapter 6 include: calculating controlled direct
effects (M.A. Hernan & Robins, 2017; Petersen, Sinisi, & Laan, 2006; Robins &
Greenland, 1992; Tchetgen Tchetgen & Vanderweele, 2014; T. VanderWeele, 2015; T. J.
VanderWeele, 2012; Vanderweele et al., 2014) and/or implementing Cheng Models
(wherein the average causal effect of known and established causes are included to
normalize estimated treatment effects) (Cheng, 1997; Cheng & Novick, 1990; C. N.
Glymour, 2001; Holyoak & Cheng, 2011).
7.4

Conclusion
Better detection methods in pharmacovigilance, if implemented appropriately,

should result in better public health and less of an onerous burden stemming from adverse
drug events. Enhanced methods for drug/adverse event detection using more granular
data would also permit regulatory agencies to prioritize potentially causal drug/adverse
event relationships for critical review more precisely owing to their severity and
prevalence. Given the extent of the exposed population, an improvement of even a few
percentage points could potentially save the lives of many thousands of our loved ones
per year.
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Appendix: Causal Graph Examples
Stochastically selected graphs of causal models instantiated with EHR data.

151

152

